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Abstract 
 
Background: Previous studies have been unclear about the cardiovascular risks for 
metabolically healthy obese individuals.  
Objectives: We aimed to examine the associations of metabolically healthy obese with 4 
different presentations of incident cardiovascular disease in a contemporary population.   
Methods: We used linked electronic health records (1995 to 2015) in The Health Improvement 
Network (THIN) to assemble a cohort of 3.5 million individuals, 18 years or older and initially 
free from cardiovascular disease. We created body size phenotypes defined by BMI categories 
(underweight, normal weight, overweight and obesity) and three metabolic abnormalities 
(diabetes, hypertension, and hyperlipidemia). The primary endpoints were the first record of one 
of 4 cardiovascular presentations [coronary heart disease (CHD), cerebrovascular disease, heart 
failure, and peripheral vascular disease (PVD)].  
Results: During a mean follow-up period of 5.4 years, obese individuals with 0 metabolic 
abnormalities had a higher risk of CHD (multivariable-adjusted hazard ratio (HR) 1.49, 95% CI 
1.45, 1.54), cerebrovascular disease (1.07, 95% CI 1.04, 1.11) and heart failure (1.96, 95% CI 
1.86, 2.06) compared to normal weight individuals with 0 metabolic abnormalities. Risk of CHD, 
cerebrovascular disease and heart failure in normal weight, overweight and obese individuals 
increased with increasing number of metabolic abnormalities.  
Conclusion: Metabolically healthy obese individuals had a higher risk of coronary heart disease, 
cerebrovascular disease and heart failure than normal weight metabolically healthy individuals. 
Even individuals who are normal weight can have metabolic abnormalities, and have similar 
risks for cardiovascular disease events. 
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Condensed abstract 
Whether individuals who are metabolically healthy obese (MHO) are associated with excess risk 
of cardiovascular disease remains a subject of debate. The present study of 3.5 million adults 
examines and compares associations between body size phenotypes with or without metabolic 
abnormalities and incident cardiovascular disease. Our results suggest that individuals who are 
MHO are at higher risk of coronary heart disease, cerebrovascular disease and heart failure than 
normal weight metabolically healthy individuals. Clinicians additionally need to be aware that 
individuals with a normal BMI can have metabolic abnormalities, and therefore be at high risk 
for cardiovascular disease events. 
 
Abbreviations 
MHO= metabolically healthy obese 
PVD= peripheral vascular disease  
THIN= The Health Improvement Network 
BMI= body mass index  
CVD= cardiovascular disease  
HR= hazard ratio  
CI= 95% confidence interval  
CHD= coronary heart disease   
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Introduction 
Obesity, an established risk factor for cardiovascular diseases (1), has been increasing 
globally over the past four decades (2). Metabolic abnormalities such as hypertension, 
dyslipidemia, and dysglycemia are known to mediate its effects, (3) however the clustering of 
obesity-related metabolic abnormalities varies widely among obese individuals. A subset of 
obese individuals without obesity-related metabolic abnormalities are often referred to as being 
“metabolically healthy obese” (MHO) (4-8). 
Three meta-analyses (9-11), have demonstrated that compared with metabolically healthy 
normal-weight individuals, obese individuals are at increased risk for cardiovascular disease 
events. Whether MHO is associated with excess risk of cardiovascular disease remains a subject 
of debate, because of important limitations to the evidence base. The main limitation is the 
inconsistent definition of metabolic health across studies. Previous studies have also not 
compared the association of MHO and a wide range of cardiovascular disease events such as 
cerebrovascular disease, heart failure, and peripheral vascular disease (PVD). Additionally, 
potential confounders have been inconsistently controlled for across studies, and there are a 
limited number of studies that have examined other metabolically defined body size phenotypes. 
We sought to address these limitations in a large contemporary cohort, based on linked 
electronic health records, which combine routine information about diagnoses, risk factors, and 
medication use with future cardiovascular disease events. Our objective was to examine 
associations between body size phenotypes (underweight, normal weight, overweight and obese) 
with or without metabolic abnormalities (diabetes, hypertension, hyperlipidemia) and incident 
coronary heart disease (angina, ischemic heart disease, myocardial infarction), cerebrovascular 
disease (transient ischemic attack, ischemic stroke, haemorrhagic stroke), heart failure, and 
peripheral vascular disease. We tested the hypothesis that compared with metabolically healthy 
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(i.e. no metabolic abnormalities) normal weight individuals, MHO individuals are at increased 
risk for cardiovascular disease events. 
Methods 
Study design and setting 
We undertook a cohort study with prospectively collected data from The Health 
Improvement Network database (THIN), which contains computerized  primary care records 
from primary care physicians who use the Vision IT system and have agreed at the practice level 
to participate [covering 6.2% of the United Kingdom (UK) population]. THIN captures 
diagnoses, prescriptions, and tests from primary care, and referrals to specialists, hospital 
admissions, and diagnoses made in secondary care, which are typically reported back to the 
primary care physician. They record lifestyle (e.g. smoking status) and anthropometric 
measurements (e.g. height, weight); these measurements could be recorded at patient 
registration, opportunistically during care, or as deemed clinically relevant by the primary care 
physicians. THIN data is representative of the UK population (12), and comparisons to external 
statistics and other independent studies have shown that both the clinical diagnostic and 
prescribing information is well recorded and accurate (12,13). Data collection began in January 
1995, and we used all data to September, 2015. For this study, approval was obtained via THIN’s 
independent Scientific Review Committee in August 2016 (SRC reference number: 
16THIN078). 
Participants 
We included all persons in THIN aged 18 years older with BMI data. Patients were only 
eligible to take part once their general practices had implemented the VISION IT system.  Study 
entry began 12 months after registration to minimize the chance that cardiovascular disease 
events recorded after registration reflected pre-existing or historical disease. We assigned the 
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first BMI record from the registration date or the first one recorded after the VISION IT system 
was initiated. Individuals with any record of cardiovascular disease events before study entry 
were excluded. 
Exposure 
BMI was defined as body weight (kilograms) divided by height (meters) squared, and 
expressed in kg/m
2
 at study entry. We defined individuals as having diabetes and hypertension 
by coded diagnoses (READ codes) recorded in THIN at study entry (Online Table 1). We 
defined individuals as having hyperlipidemia on the basis of whether individuals had  specific 
prescription records of lipid-lowering agents. Individuals who developed diabetes, hypertension 
or hyperlipidemia during follow-up were analyzed according to their baseline status of no 
diabetes, hypertension or hyperlipidemia. 
Body size phenotypes were defined using WHO criteria as follows: underweight (BMI < 
18.5 kg/m
2
), normal-weight (18 kg/m
2 
>BMI<25 kg/m
2
), overweight (25 kg/m
2 ≥ BMI 
< 30 kg/m2) and obese (BMI ≥ 30 kg/m2). The three metabolic abnormalities were summed to 
create a metabolic abnormalities score (0, 1, 2 and 3). Persons were categorized into 14 body size 
phenotypes: underweight with 0 metabolic abnormalities, underweight with 1 or more metabolic 
abnormalities, normal weight with 0 metabolic abnormalities, normal weight with 1 metabolic 
abnormality, normal weight with 2 metabolic abnormalities, normal weight with 3 metabolic 
abnormalities, overweight with 0 metabolic abnormalities, overweight with 1 metabolic 
abnormality, overweight with 2 metabolic abnormalities, overweight with 3 metabolic 
abnormalities, obese with 0 metabolic abnormalities, obese with 1 metabolic abnormality, obese 
with 2 metabolic abnormalities, and obese with 3 metabolic abnormalities.  
Outcomes 
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The endpoints were the first record of one of the following 4 presentations of 
cardiovascular disease: coronary heart disease (angina, ischemic heart disease, myocardial 
infarction), cerebrovascular disease (transient ischemic attack, ischemic stroke, hemorrhagic 
stroke), heart failure, and peripheral vascular disease. Any events occurring after the first 
cardiovascular disease presentation were ignored. Endpoint definitions are described in Online 
Table 2.  
Covariates 
Participant’s age, sex, self-reported smoking status, and social deprivation were included 
in models. Data recorded at study entry was used to classify participants as never smokers, ex-
smokers, or current smokers.  Social deprivation was included as quintiles of the index of 
multiple deprivation (14), a score calculated for each participant's neighborhood on the basis of 
social indices such as income, education, and employment. 
Statistical analysis 
Of the 4,091,344 million individuals aged 18 years or older in THIN without a history of 
CVD, we excluded persons with missing data on sex (128,458/4.09 million [3.1%]), BMI 
(161,699/4.09 million [4.0%]), smoking (53,262 /4.09 million [1.3%]) and social deprivation 
(252,148 /4.09 million [6.2%]).  After these exclusions, there remained a final sample of 
3,495,777 participants (85.4% of the eligible sample). Those excluded due to missing 
information were less likely to be male (41.4% vs. 43.1%; p < 0.001), younger (41.1 years vs. 
44.7 years; p < 0.001), have a lower BMI (25.9 kg/m
2
 vs. 26.4 kg/m
2
; p < 0.001), more likely to 
belong to the most deprived quintile (14.5% vs. 14.0%; p < 0.001) and more likely to be current 
smokers (25.1% vs. 24.6%; p < 0.001). 
Follow-up was censored at the occurrence of first cardiovascular disease endpoint, death, 
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de-registration from the practice, or the last data collection for the practice, whichever occurred 
first. We used Cox proportional hazard models to calculate hazard ratios (HRs) and 95% 
confidence intervals (CIs) for associations between each body size phenotype with or without 
metabolic abnormalities and cardiovascular disease event. We adjusted for age at BMI record, 
sex, self-reported smoking and social deprivation. We assessed the proportional hazards 
assumption by visually checking the Kaplan-Meier curves and tested it using Schoenfeld 
residuals. In sub-group analyses, we stratified associations by sex and age (<65 y, ≥ 65 y). The 
cut-off at 65 years was chosen as this is commonly used to designate an individual as an older 
person (15). In sensitivity analyses we defined metabolic status by diagnostic or prescription 
codes as well as laboratory or physical measurements; adjusted analyses for hormone 
replacement therapy (HRT) and oral contraceptives, respectively; and excluded patients with 
type 1 diabetes. Residual confounding by cigarette smoking has been suggested as a possible 
explanation for inconsistent associations between obesity and PVD (16). Excess risk for 
cardiovascular disease events associated with low BMI can also be associated with smoking-
related diseases (such as chronic obstructive pulmonary disease (COPD) and lung cancer). 
Therefore, in sensitivity analyses we examined body size phenotypes with or without metabolic 
abnormalities and cardiovascular disease events only among individuals who reported never 
smoking cigarettes.   
Results 
Among 3,495,777 individuals, 2.7% were classified as underweight with no metabolic 
abnormalities, 37.7% were classified as normal weight with no metabolic abnormalities, 25.7% 
were classified as overweight with no metabolic abnormalities, and 14.8% were classified as 
obese with no metabolic abnormalities (Online Table 3). The prevalence of 3 metabolic 
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abnormalities was rare regardless of the weight category, with underweight individuals having 
the lowest (0%) (Online Table 3). Metabolically healthy obese individuals were more likely to be 
younger, male, current smokers and socioeconomically deprived compared with metabolically 
unhealthy obese individuals (Table 1). 
There were 154,051 (4.4%) deaths and 1,182,658 (30.8%) patients transferred out of their 
general practice.  Over a mean 5.4 year follow-up, there were 165,302 initial cardiovascular 
disease presentations: 61,546(37.2%) developed CHD, 54,705 (33.1%) developed 
cerebrovascular disease, 25,254 (15.3%) developed heart failure and 23,797 (14.4%) developed 
PVD. Incidence rates of cardiovascular disease events by body size phenotype and metabolic 
status are shown in Online Tables 5-7. Among initially metabolically healthy overweight 
individuals, approximately 1.9% of developed diabetes, 9.4% developed hyperlipidemia, and 
7.2% developed hypertension. Among initially MHO individuals, approximately 5.6% developed 
diabetes, 11.5% developed hyperlipidemia, and 10.5% developed hypertension. 
The Central Illustration depicts the associations between the 14 body size phenotypes 
with or without metabolic abnormalities and cardiovascular disease events (CHD, 
cerebrovascular disease, heart failure, and PVD) with the normal weight 0 metabolic 
abnormalities group as the reference. 
Coronary heart disease 
Individuals who were overweight with 0 metabolic abnormalities (HR 1.30, 95% CI 1.27, 
1.34) and obese with 0 metabolic abnormalities (HR 1.49, 95% CI 1.45, 1.54), had an increased 
risk of coronary heart disease, compared to normal weight individuals with no metabolic 
abnormalities after adjustment for potential confounders (central illustration). Risk of coronary 
heart disease in the normal weight, overweight and obese groups increased with increased 
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number of metabolic abnormalities (Central Illustration).  
Cerebrovascular disease 
Individuals who were underweight (HR 1.31, 95% CI 1.23, 1.40) and obese with 0 
metabolic abnormalities (HR 1.07, 95% CI 1.04, 1.11) had an increased risk of cerebrovascular 
disease, compared to normal weight individuals with no metabolic abnormalities after adjustment 
for potential confounders (central illustration). Risk of cerebrovascular disease in the normal 
weight, overweight and obese groups increased with the increasing number of metabolic 
abnormalities (Central Illustration). 
Heart failure 
Individuals who were underweight (HR 1.36, 95% CI 1.23, 1.51), overweight with 0 
metabolic abnormalities (HR 1.11, 95% CI 1.06, 1.16) and obese with 0 metabolic abnormalities 
(HR 1.96, 95% CI 1.86, 2.06) had an increased risk of heart failure, compared to normal weight 
individuals with no metabolic abnormalities after adjustment for potential confounders (central 
illustration). Risk of heart failure in the normal weight, overweight and obese groups increased 
with increased number of metabolic abnormalities (Central Illustration). 
Peripheral vascular disease  
Individuals who were underweight had an increased risk of PVD (HR 1.49, 95% CI 1.36, 
1.63), compared to normal weight individuals with no metabolic abnormalities after adjustment 
for potential confounders (central illustration).  Individuals who were overweight with 0 
metabolic abnormalities (adjusted HR 0.92, 95% CI 0.88, 0.96) and obese with 0 metabolic 
abnormalities (adjusted HR 0.91, 95% CI 0.86, 0.96) had a decreased risk of PVD compared to 
normal weight individuals with no metabolic abnormalities (central illustration). Risk of PVD 
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increased with the number of metabolic abnormalities in the normal weight, overweight and 
obese groups (central illustration).  
Sub-group analyses 
We undertook several sub-group analyses (Online Tables 8-15). There was some 
evidence that the risk of cerebrovascular disease in overweight and obese individuals without 
metabolic abnormalities, heart failure in overweight individuals without metabolic abnormalities, 
differed significantly by sex. Females had stronger positive associations with cerebrovascular 
disease and heart failure compared to males. There was some evidence that the risk of CHD, 
cerebrovascular disease, heart failure and PVD in overweight and obese individuals without 
metabolic abnormalities differed significantly by age. Individuals < 65 years had significantly 
stronger positive associations with CHD, cerebrovascular disease, heart failure and PVD than 
individuals ≥ 65 years. Among overweight and obese individuals without metabolic 
abnormalities, age-stratified analyses revealed significant positive associations with PVD.  
Sensitivity analyses 
When metabolic status was derived from diagnostic codes or prescription records as well as  
laboratory/physical measurements, the magnitude of associations between the body size 
phenotypes and metabolic status with CHD, cerebrovascular disease, heart failure and PVD were 
generally larger (Online Tables 9, 11, 13, & 15). For metabolically healthy overweight or obese 
groups, the negative association with PVD became non-significant (Online Table 15). Further 
adjustment for HRT or oral contraceptives did not significantly change the estimates (Online 
Tables 9 & 11). Exclusion of participants with type 1 diabetes did not significantly alter the 
results (Online Tables 9, 11, 13, & 15). In analyses restricted to individuals who reported they 
never smoked cigarettes, individuals who were obese with no metabolic abnormalities, had a 
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significantly stronger positive association with PVD (Online Table 15). For individuals who 
were underweight with no metabolic abnormalities, we repeated analyses only in those who 
reported they never smoked cigarettes. This did not significantly alter the results, with the 
exception that the positive association with cerebrovascular disease became non-significant 
(Online Table 15). 
Discussion 
In this study of approximately 3.5 million individuals accruing 165,302 cardiovascular 
disease events during 5.4 years average follow-up, we showed that individuals who are obese 
and classified as metabolically healthy (either no metabolic abnormalities, 1 or 2) are still at an 
increased risk for CHD, cerebrovascular disease and heart failure compared with individuals who 
are normal weight with no metabolic risk factors. These associations were not dependent on 
participants’ sex. Approximately, one in ten who were normal weight had metabolic 
abnormalities and had increased risks for CHD, cerebrovascular disease, heart failure and PVD 
compared to normal weight individuals without metabolic abnormalities. 
Although three meta-analyses (9-11) have assessed the risks of cardiovascular disease for 
the MHO phenotype, these each had limitations. The meta-analysis of Kramer et al (10) 
demonstrated that MHO individuals had increased risk for cardiovascular disease events 
compared with metabolically healthy normal-weight individuals. However, their findings were 
controversial. The meta-analysis roughly merged cardiovascular disease events and all-cause 
mortality together to calculate the pooled risk estimates for MHO individuals. Another limitation 
of the meta-analysis was the fact that it did not adequately adjust for important baseline factors, 
including age, and sex. Similarly, in the meta-analysis of Fan et al (11), they did not differentiate 
cardiovascular disease events and all-cause death events separately, but merged them together to 
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calculate the pooled risk estimate. Whereas, in our study we examined MHO with the incidence 
of specific cardiovascular disease events (i.e. CHD, cerebrovascular disease, heart failure and 
PVD) based on validated electronic health records (17-19). We were also able to adjust for 
important baseline factors including age, sex, smoking status and socio-economic deprivation. 
Recently, Zheng et al (9) meta-analysis attempted to examine the association between MHO and 
cardiovascular disease events in only studies using the strictest definition for metabolic health 
(absence of all metabolic abnormalities). They found an insignificant association between MHO 
and cardiovascular disease events, however only 2 studies provided data and, as such, the 
statistical power was limited to detect significant associations. In our study, we had 
unprecedented statistical power to examine obese individuals classified by the number of 
metabolic abnormalities, potentially reflecting several definitions of the ‘metabolically healthy’ 
phenotype in relation to a range of cardiovascular disease events. 
Being metabolically unhealthy, regardless of BMI, generally conferred increased risk for 
cardiovascular disease events and normal weight status did not necessarily indicate metabolic 
health. Some individuals with normal weight have previously been reported to have elevated 
metabolic abnormalities (20,21). In the United States, the Preventive Services Task Force 
currently recommends that clinicians in primary care settings use overweight and obesity as the 
main criteria to screen adults for abnormal blood glucose as part of cardiovascular risk 
assessment (22). This could result in the failure to identify metabolic abnormalities in many 
patients.  Early detection and management of normal weight individuals with metabolic 
abnormalities may therefore be beneficial in the prevention of cardiovascular disease events. We 
found that underweight individuals had an increased risk of cerebrovascular disease, heart 
failure, and PVD. The impact of underweight on cardiovascular disease events has been 
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understudied, with most previous research not evaluating underweight individuals separately 
from normal weight individuals. (3,23) Excess risk for cardiovascular disease events associated 
with low BMI may be related to smoking-related diseases such as chronic obstructive pulmonary 
disease (COPD) and lung cancer. To minimize this possibility, in sensitivity analyses we only 
examined the association between underweight with no metabolic abnormalities and 
cardiovascular disease events restricted to individuals who never reported smoking cigarettes. 
The results were unchanged from the main results with the exception that underweight 
individuals with no metabolic abnormalities now had a non-significant risk for cerebrovascular 
disease.  
Our finding that obesity was associated with a lower risk of PVD was surprising, 
considering that it may influence the atherosclerotic process (24). Previous studies on the 
association between obesity and PVD have been inconsistent (16). In the Israeli Ischemic Heart 
Disease Project (25), those with new-onset intermittent claudication had a higher BMI than those 
who remained symptom free. Other large population-based studies however have failed to 
demonstrate that obesity increases risk for PVD (26-28), with some studies even reporting a 
reduction in risk for PVD (29-31). In the Framingham Study Cohort, relative weight was found 
to be inversely associated with intermittent claudication (30). One potential explanation for this 
is residual confounding by cigarette smoking (cigarette smoking is strongly associated with both 
PVD and lower BMI) (16). In sensitivity analyses, restricted to individuals who were obese with 
no metabolic abnormalities and reported never smoking cigarettes, risk for PVD was increased, 
compared to normal weight individuals with no metabolic abnormalities. 
To the best of our knowledge, this is the largest prospective study of the association 
between body size phenotypes with or without metabolic abnormalities (including MHO) and a 
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range of incident cardiovascular disease events, with unprecedented precision and power. 
Dividing our participants into four BMI groups according to the classification provided by World 
Health Organization, gave us the possibility of a more granular analysis of the CVD risk in the 
different body size phenotypes.  
Several limitations of our study however require careful consideration. BMI has many 
advantages as a surrogate of body fat, such as simplicity and reproducibility (32) however we are 
unable to distinguish differences between high percentage of body fat and preserved or increased 
lean mass, particularly in participants with a BMI <30 kg/m
2
. Even though patients registered in 
THIN are representative of the general UK adult population (12), persons with a BMI 
measurement might not necessarily be representative of the general population. BMI data if not 
recorded at registration, tends to be opportunistically recorded (i.e. recorded when the patient is 
attending for other reasons or when the matter is of direct clinical importance). We limited this 
possibility by only using the first BMI recorded from the registration date (because they would 
have probably been recorded for administrative and not health reasons). Our findings are drawn 
from baseline measurements of BMI and metabolic abnormalities. Considering the difficulty in 
losing weight, it is more likely that individuals transition to higher weight (i.e. normal 
weight/overweight to obese) categories than transition to lower weight categories (i.e. obese to 
overweight/normal weight) (10). Thus, the potential misclassification effect of changes in weight 
over time was probably conservative. In our study, a small proportion of individuals who were 
initially metabolically healthy overweight or obese did progress to metabolically unhealthy 
overweight or obesity. Therefore, due to changes in metabolic abnormalities, a degree of 
misclassification, did occur. We did not have access to appropriate data on diet or physical 
activity, and therefore could not examine for example, whether physical activity could modify 
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the association between MHO and incident cardiovascular disease. Patients were defined as 
having diabetes or hypertension utilizing diagnostic codes and hyperlipidemia was defined 
utilizing prescription codes.  Given that a proportion of individuals with metabolic abnormalities 
may be undiagnosed in the UK (33,34) we used available measures of HbA1c, blood pressure 
and serum lipids to minimize misclassification error. Additionally, given that improvement of 
glycemic, blood pressure, or lipid control obtained through treatment can prevent cardiovascular 
disease events in the long term, we may therefore expect that optimally treated/controlled 
patients would have a reduced risk of developing a cardiovascular disease events compared to 
those who are uncontrolled, and therefore our HR estimates would be conservative. The 
proportion of participants who transferred out of their practice was high (30.8%).  However, the 
difference between the proportion of participants who were obese with no metabolic 
abnormalities transferring out of their practice and those who remained in their practice was 
small (13.0% vs. 16.0%), and therefore less likely to bias the HRs substantially.  
Taking into consideration the genetic heterogeneity related to obesity (35), it is not 
implausible to assume that a distinct, benign phenotype in terms of CVD risk may be present. Of 
the body size phenotypes, MHO has been the most commonly examined phenotype (36), and it 
has been suggested that the concept of metabolically healthy obesity might be important in the 
stratification of individuals in the clinical treatment of obesity (36). Some researchers have called 
for a shift in the public health focus away from markers of adiposity such as BMI (37) and 
suggest that health providers prescribing weight loss interventions may be misusing time and 
resources (38). Our study robustly challenges the assertion that MHO is a benign condition and 
adds to the evidence base that MHO is a high-risk state for future cardiovascular disease events.  
Conclusions 
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Individuals who are obese with no metabolic abnormalities are at higher risk of coronary 
heart disease, cerebrovascular disease and heart failure than normal weight metabolically healthy 
persons. Clinicians need to be aware that individuals who would otherwise be considered non-
obese, based on a normal BMI, can have metabolic abnormalities, and therefore also be at high 
risk for cardiovascular disease events. 
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Perspectives 
Competency in patient care and medical knowledge: Metabolically healthy obesity is a 
unique body size phenotype that apparently protects people from the metabolic complications of 
obesity including cardiovascular disease. However, whether these individuals are truly at less 
risk of cardiovascular disease has remained controversial. Our study of 3.5 million electronic 
primary care records suggest individuals who are obese and classified as metabolically healthy 
(either no metabolic abnormalities, 1 or 2) are still at an increased risk for coronary heart disease, 
cerebrovascular disease and heart failure compared with individuals who are normal weight with 
no metabolic risk factors.  Individuals who are normal weight can also have metabolic 
abnormalities, and be at high risk for cardiovascular disease events. 
Translational Outlook: Large and long-term cohort trials are still required to determine the 
effect of weight loss on risk of developing cardiovascular disease events among metabolically 
healthy obese individuals.  
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Figure Legend 
Central Illustration: Association of body size phenotypes and metabolic status with 
cardiovascular disease events in 3.5 million UK adults.  Analyses adjusted for age, sex, 
smoking status and social deprivation. The reference category is normal weight, 0 metabolic 
abnormalities. 
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Table 1 Baseline characteristics of the study population, by body size phenotypes and metabolic health status  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BMI= body mass index 
*Obese with 0 metabolic abnormalities 
†Obese with 1 or more metabolic abnormalities 
 Underweight Normal weight Overweight Metabolically 
healthy and obese* 
Metabolically 
unhealthy and obese
† 
Mean age (SD), (years) 38.0 (20.3) 41.3 (17.6) 47.7 (16.6) 42.6 (13.8) 58.6 (12.6) 
Sex      
Male 24,753 (26.3) 547,600 (37.0) 603,492 (52.1) 301,974 (58.4) 114,196 (46.6) 
Female 69,276 (73.7) 932,626 (63.0) 555,324 (47.9) 215,470 (41.6) 131,066 (53.4) 
Smoking status      
Never smoker 51,614 (54.9) 842,573 (56.9) 637,442 (55.0) 284,510 (55.0) 133,878 (54.6) 
Ex- smoker 10,075 (10.7) 235,766 (15.9) 257,903 (22.3) 109,051 (21.1) 73,015 (29.8) 
Current smoker 32,340 (34.4) 401,887 (27.2) 263,471 (22.7) 123,883 (23.9) 38,369 (15.6) 
Social deprivation 
quintile 
     
1 (least deprived) 16,736 (17.8) 352,906 (23.8) 295,984 (25.5) 110,089  (21.3) 54,712 (22.3) 
2 16,119 (17.1) 303,729  (20.5) 256,192 (22.1) 104,285  (20.2) 52,844  (21.6) 
3 20,083 (21.4) 318,076 (21.5) 248,836 (21.5) 114,512 (22.1) 53,628 (21.9) 
4 22,583 (24.0) 293,845 (19.9) 212,177  (18.3) 108,679  (21.0) 49,278 (20.1) 
5 (most deprived) 18,508 (19.7) 211,670 (14.3) 145,627 (12.6) 79,879  (15.4) 34,800 (14.2) 
Mean BMI (SD), kg/m2 17.4 (1.0) 22.3 (1.7) 27.2 (1.4) 34.4 (4.5) 34.9 (4.8) 
Central Illustration : Association of body size phenotypes and metabolic status with cardiovascular disease events in 3.5 million UK adults. 
Analyses adjusted for age, sex, smoking status and social deprivation. The reference category is normal weight, 0 metabolic abnormalities.
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Overweight, 3 metabolic abnormalities
Obese, 0 metabolic abnormalities
Obese, 1 metabolic abnormality
Obese, 2 metabolic abnormalities
Obese, 3 metabolic abnormalities
Adjusted HR (95% CI)
1.0 1.5 2.0 2.5 3.0
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Table S1 Overview of codes used to define metabolic abnormalities 
   
Metabolic  
abnormality 
READ 
code 
Description 
   
Diabetes C10..00 Diabetes mellitus 
 C100.00 Diabetes mellitus with no mention of complication 
 C100000 Diabetes mellitus, juvenile type, no mention of complication 
 C100011 Insulin dependent diabetes mellitus 
 C100100 Diabetes mellitus, adult onset, no mention of complication 
 C100111 Maturity onset diabetes 
 C100112 Non-insulin dependent diabetes mellitus 
 C100z00 Diabetes mellitus NOS with no mention of complication 
 C101.00 Diabetes mellitus with ketoacidosis 
 C101000 Diabetes mellitus, juvenile type, with ketoacidosis 
 C101100 Diabetes mellitus, adult onset, with ketoacidosis 
 C101y00 Other specified diabetes mellitus with ketoacidosis 
 C101z00 Diabetes mellitus NOS with ketoacidosis 
 C102.00 Diabetes mellitus with hyperosmolar coma 
 C102000 Diabetes mellitus, juvenile type, with hyperosmolar coma 
 C102100 Diabetes mellitus, adult onset, with hyperosmolar coma 
 C102z00 Diabetes mellitus NOS with hyperosmolar coma 
 C103.00 Diabetes mellitus with ketoacidotic coma 
 C103000 Diabetes mellitus, juvenile type, with ketoacidotic coma 
 C103100 Diabetes mellitus, adult onset, with ketoacidotic coma 
 C103y00 Other specified diabetes mellitus with coma 
 C103z00 Diabetes mellitus NOS with ketoacidotic coma 
 C104.00 Diabetes mellitus with renal manifestation 
 C104.11 Diabetic nephropathy 
 C104000 Diabetes mellitus, juvenile type, with renal manifestation 
 C104100 Diabetes mellitus, adult onset, with renal manifestation 
 C104y00 Other specified diabetes mellitus with renal complications 
 C104z00 Diabetes mellitus with nephropathy NOS 
 C105.00 Diabetes mellitus with ophthalmic manifestation 
 C105000 Diabetes mellitus, juvenile type, + ophthalmic manifestation 
 C105100 Diabetes mellitus, adult onset, + ophthalmic manifestation 
 C105y00 Other specified diabetes mellitus with ophthalmic complicatn 
 C105z00 Diabetes mellitus NOS with ophthalmic manifestation 
 C106.00 Diabetes mellitus with neurological manifestation 
 C106.11 Diabetic amyotrophy 
 C106.12 Diabetes mellitus with neuropathy 
 C106.13 Diabetes mellitus with polyneuropathy 
 C106000 Diabetes mellitus, juvenile, + neurological manifestation 
 C106100 Diabetes mellitus, adult onset, + neurological manifestation 
 C106y00 Other specified diabetes mellitus with neurological comps 
  2 
 C106z00 Diabetes mellitus NOS with neurological manifestation 
 C108.00 Insulin dependent diabetes mellitus 
 C108.11 IDDM-Insulin dependent diabetes mellitus 
 C108.12 Type 1 diabetes mellitus 
 C108.13 Type I diabetes mellitus 
 C108000 Insulin-dependent diabetes mellitus with renal complications 
 C108011 Type I diabetes mellitus with renal complications 
 C108012 Type 1 diabetes mellitus with renal complications 
 C108100 Insulin-dependent diabetes mellitus with ophthalmic comps 
 C108111 Type I diabetes mellitus with ophthalmic complications 
 C108112 Type 1 diabetes mellitus with ophthalmic complications 
 C108200 Insulin-dependent diabetes mellitus with neurological comps 
 C108211 Type I diabetes mellitus with neurological complications 
 C108212 Type 1 diabetes mellitus with neurological complications 
 C108300 Insulin dependent diabetes mellitus with multiple complicatn 
 C108311 Type I diabetes mellitus with multiple complications 
 C108312 Type 1 diabetes mellitus with multiple complications 
 C108400 Unstable insulin dependent diabetes mellitus 
 C108411 Unstable type I diabetes mellitus 
 C108412 Unstable type 1 diabetes mellitus 
 C108500 Insulin dependent diabetes mellitus with ulcer 
 C108511 Type I diabetes mellitus with ulcer 
 C108512 Type 1 diabetes mellitus with ulcer 
 C108700 Insulin dependent diabetes mellitus with retinopathy 
 C108711 Type I diabetes mellitus with retinopathy 
 C108712 Type 1 diabetes mellitus with retinopathy 
 C108800 Insulin dependent diabetes mellitus - poor control 
 C108811 Type I diabetes mellitus - poor control 
 C108812 Type 1 diabetes mellitus - poor control 
 C108900 Insulin dependent diabetes maturity onset 
 C108911 Type I diabetes mellitus maturity onset 
 C108912 Type 1 diabetes mellitus maturity onset 
 C108A00 Insulin-dependent diabetes without complication 
 C108A11 Type I diabetes mellitus without complication 
 C108A12 Type 1 diabetes mellitus without complication 
 C108B00 Insulin dependent diabetes mellitus with mononeuropathy 
 C108B11 Type I diabetes mellitus with mononeuropathy 
 C108B12 Type 1 diabetes mellitus with mononeuropathy 
 C108C00 Insulin dependent diabetes mellitus with polyneuropathy 
 C108C11 Type I diabetes mellitus with polyneuropathy 
 C108C12 Type 1 diabetes mellitus with polyneuropathy 
 C108D00 Insulin dependent diabetes mellitus with nephropathy 
 C108D11 Type I diabetes mellitus with nephropathy 
 C108D12 Type 1 diabetes mellitus with nephropathy 
 C108E00 Insulin dependent diabetes mellitus with hypoglycaemic coma 
 C108E11 Type I diabetes mellitus with hypoglycaemic coma 
  3 
 C108E12 Type 1 diabetes mellitus with hypoglycaemic coma 
 C108F00 Insulin dependent diabetes mellitus with diabetic cataract 
 C108F11 Type I diabetes mellitus with diabetic cataract 
 C108F12 Type 1 diabetes mellitus with diabetic cataract 
 C108G00 Insulin dependent diab mell with peripheral angiopathy 
 C108G11 Type I diabetes mellitus with peripheral angiopathy 
 C108G12 Type 1 diabetes mellitus with peripheral angiopathy 
 C108H00 Insulin dependent diabetes mellitus with arthropathy 
 C108H11 Type I diabetes mellitus with arthropathy 
 C108H12 Type 1 diabetes mellitus with arthropathy 
 C108J00 Insulin dependent diab mell with neuropathic arthropathy 
 C108J11 Type I diabetes mellitus with neuropathic arthropathy 
 C108J12 Type 1 diabetes mellitus with neuropathic arthropathy 
 C108y00 Other specified diabetes mellitus with multiple comps 
 C108z00 Unspecified diabetes mellitus with multiple complications 
 C109.00 Non-insulin dependent diabetes mellitus 
 C109.11 NIDDM - Non-insulin dependent diabetes mellitus 
 C109.12 Type 2 diabetes mellitus 
 C109.13 Type II diabetes mellitus 
 C109000 Non-insulin-dependent diabetes mellitus with renal comps 
 C109011 Type II diabetes mellitus with renal complications 
 C109012 Type 2 diabetes mellitus with renal complications 
 C109100 Non-insulin-dependent diabetes mellitus with ophthalm comps 
 C109111 Type II diabetes mellitus with ophthalmic complications 
 C109112 Type 2 diabetes mellitus with ophthalmic complications 
 C109200 Non-insulin-dependent diabetes mellitus with neuro comps 
 C109211 Type II diabetes mellitus with neurological complications 
 C109212 Type 2 diabetes mellitus with neurological complications 
 C109300 Non-insulin-dependent diabetes mellitus with multiple comps 
 C109311 Type II diabetes mellitus with multiple complications 
 C109312 Type 2 diabetes mellitus with multiple complications 
 C109400 Non-insulin dependent diabetes mellitus with ulcer 
 C109411 Type II diabetes mellitus with ulcer 
 C109412 Type 2 diabetes mellitus with ulcer 
 C109600 Non-insulin-dependent diabetes mellitus with retinopathy 
 C109611 Type II diabetes mellitus with retinopathy 
 C109612 Type 2 diabetes mellitus with retinopathy 
 C109700 Non-insulin dependent diabetes mellitus - poor control 
 C109711 Type II diabetes mellitus - poor control 
 C109712 Type 2 diabetes mellitus - poor control 
 C109800 Reaven's syndrome 
 C109900 Non-insulin-dependent diabetes mellitus without complication 
 C109911 Type II diabetes mellitus without complication 
 C109912 Type 2 diabetes mellitus without complication 
 C109A00 Non-insulin dependent diabetes mellitus with mononeuropathy 
 C109A11 Type II diabetes mellitus with mononeuropathy 
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 C109A12 Type 2 diabetes mellitus with mononeuropathy 
 C109B00 Non-insulin dependent diabetes mellitus with polyneuropathy 
 C109B11 Type II diabetes mellitus with polyneuropathy 
 C109B12 Type 2 diabetes mellitus with polyneuropathy 
 C109C00 Non-insulin dependent diabetes mellitus with nephropathy 
 C109C11 Type II diabetes mellitus with nephropathy 
 C109C12 Type 2 diabetes mellitus with nephropathy 
 C109D00 Non-insulin dependent diabetes mellitus with hypoglyca coma 
 C109D11 Type II diabetes mellitus with hypoglycaemic coma 
 C109D12 Type 2 diabetes mellitus with hypoglycaemic coma 
 C109E00 Non-insulin depend diabetes mellitus with diabetic cataract 
 C109E11 Type II diabetes mellitus with diabetic cataract 
 C109E12 Type 2 diabetes mellitus with diabetic cataract 
 C109G00 Non-insulin dependent diabetes mellitus with arthropathy 
 C109G11 Type II diabetes mellitus with arthropathy 
 C109G12 Type 2 diabetes mellitus with arthropathy 
 C109H00 Non-insulin dependent d m with neuropathic arthropathy 
 C109H11 Type II diabetes mellitus with neuropathic arthropathy 
 C109H12 Type 2 diabetes mellitus with neuropathic arthropathy 
 C109J00 Insulin treated Type 2 diabetes mellitus 
 C109J11 Insulin treated non-insulin dependent diabetes mellitus 
 C109J12 Insulin treated Type II diabetes mellitus 
 C109K00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
 C10A.00 Malnutrition-related diabetes mellitus 
 C10A000 Malnutrition-related diabetes mellitus with coma 
 C10A100 Malnutrition-related diabetes mellitus with ketoacidosis 
 C10A200 Malnutrition-related diabetes mellitus with renal complicatn 
 C10A300 Malnutrit-related diabetes mellitus wth ophthalmic complicat 
 C10A400 Malnutrition-related diabetes mellitus wth neuro complicatns 
 C10A600 Malnutrition-related diabetes mellitus with multiple comps 
 C10A700 Malnutrition-related diabetes mellitus without complications 
 C10AW00 Malnutrit-related diabetes mellitus with unspec complics 
 C10AX00 Malnutrit-relat diabetes mellitus with other spec comps 
 C10B.00 Diabetes mellitus induced by steroids 
 C10B000 Steroid induced diabetes mellitus without complication 
 C10C.00 Diabetes mellitus autosomal dominant 
 C10C.11 Maturity onset diabetes in youth 
 C10C.12 Maturity onset diabetes in youth type 1 
 C10D.00 Diabetes mellitus autosomal dominant type 2 
 C10D.11 Maturity onset diabetes in youth type 2 
 C10E.00 Type 1 diabetes mellitus 
 C10E.11 Type I diabetes mellitus 
 C10E.12 Insulin dependent diabetes mellitus 
 C10E000 Type 1 diabetes mellitus with renal complications 
 C10E011 Type I diabetes mellitus with renal complications 
 C10E012 Insulin-dependent diabetes mellitus with renal complications 
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 C10E100 Type 1 diabetes mellitus with ophthalmic complications 
 C10E111 Type I diabetes mellitus with ophthalmic complications 
 C10E112 Insulin-dependent diabetes mellitus with ophthalmic comps 
 C10E200 Type 1 diabetes mellitus with neurological complications 
 C10E211 Type I diabetes mellitus with neurological complications 
 C10E212 Insulin-dependent diabetes mellitus with neurological comps 
 C10E300 Type 1 diabetes mellitus with multiple complications 
 C10E311 Type I diabetes mellitus with multiple complications 
 C10E312 Insulin dependent diabetes mellitus with multiple complicat 
 C10E400 Unstable type 1 diabetes mellitus 
 C10E411 Unstable type I diabetes mellitus 
 C10E412 Unstable insulin dependent diabetes mellitus 
 C10E500 Type 1 diabetes mellitus with ulcer 
 C10E511 Type I diabetes mellitus with ulcer 
 C10E512 Insulin dependent diabetes mellitus with ulcer 
 C10E700 Type 1 diabetes mellitus with retinopathy 
 C10E711 Type I diabetes mellitus with retinopathy 
 C10E712 Insulin dependent diabetes mellitus with retinopathy 
 C10E800 Type 1 diabetes mellitus - poor control 
 C10E811 Type I diabetes mellitus - poor control 
 C10E812 Insulin dependent diabetes mellitus - poor control 
 C10E900 Type 1 diabetes mellitus maturity onset 
 C10E911 Type I diabetes mellitus maturity onset 
 C10E912 Insulin dependent diabetes maturity onset 
 C10EA00 Type 1 diabetes mellitus without complication 
 C10EA11 Type I diabetes mellitus without complication 
 C10EA12 Insulin-dependent diabetes without complication 
 C10EB00 Type 1 diabetes mellitus with mononeuropathy 
 C10EB11 Type I diabetes mellitus with mononeuropathy 
 C10EB12 Insulin dependent diabetes mellitus with mononeuropathy 
 C10EC00 Type 1 diabetes mellitus with polyneuropathy 
 C10EC11 Type I diabetes mellitus with polyneuropathy 
 C10EC12 Insulin dependent diabetes mellitus with polyneuropathy 
 C10ED00 Type 1 diabetes mellitus with nephropathy 
 C10ED11 Type I diabetes mellitus with nephropathy 
 C10ED12 Insulin dependent diabetes mellitus with nephropathy 
 C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma 
 C10EE11 Type I diabetes mellitus with hypoglycaemic coma 
 C10EE12 Insulin dependent diabetes mellitus with hypoglycaemic coma 
 C10EF00 Type 1 diabetes mellitus with diabetic cataract 
 C10EF11 Type I diabetes mellitus with diabetic cataract 
 C10EF12 Insulin dependent diabetes mellitus with diabetic cataract 
 C10EH00 Type 1 diabetes mellitus with arthropathy 
 C10EH11 Type I diabetes mellitus with arthropathy 
 C10EH12 Insulin dependent diabetes mellitus with arthropathy 
 C10EJ00 Type 1 diabetes mellitus with neuropathic arthropathy 
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 C10EJ11 Type I diabetes mellitus with neuropathic arthropathy 
 C10EJ12 Insulin dependent diab mell with neuropathic arthropathy 
 C10EK00 Type 1 diabetes mellitus with persistent proteinuria 
 C10EK11 Type I diabetes mellitus with persistent proteinuria 
 C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria 
 C10EL11 Type I diabetes mellitus with persistent microalbuminuria 
 C10EM00 Type 1 diabetes mellitus with ketoacidosis 
 C10EM11 Type I diabetes mellitus with ketoacidosis 
 C10EN00 Type 1 diabetes mellitus with ketoacidotic coma 
 C10EN11 Type I diabetes mellitus with ketoacidotic coma 
 C10EP00 Type 1 diabetes mellitus with exudative maculopathy 
 C10EP11 Type I diabetes mellitus with exudative maculopathy 
 C10EQ00 Type 1 diabetes mellitus with gastroparesis 
 C10EQ11 Type I diabetes mellitus with gastroparesis 
 C10ER00 Latent autoimmune diabetes mellitus in adult 
 C10F.00 Type 2 diabetes mellitus 
 C10F.11 Type II diabetes mellitus 
 C10F000 Type 2 diabetes mellitus with renal complications 
 C10F011 Type II diabetes mellitus with renal complications 
 C10F100 Type 2 diabetes mellitus with ophthalmic complications 
 C10F111 Type II diabetes mellitus with ophthalmic complications 
 C10F200 Type 2 diabetes mellitus with neurological complications 
 C10F211 Type II diabetes mellitus with neurological complications 
 C10F300 Type 2 diabetes mellitus with multiple complications 
 C10F311 Type II diabetes mellitus with multiple complications 
 C10F400 Type 2 diabetes mellitus with ulcer 
 C10F411 Type II diabetes mellitus with ulcer 
 C10F600 Type 2 diabetes mellitus with retinopathy 
 C10F611 Type II diabetes mellitus with retinopathy 
 C10F700 Type 2 diabetes mellitus - poor control 
 C10F711 Type II diabetes mellitus - poor control 
 C10F800 Reaven's syndrome 
 C10F811 Metabolic syndrome X 
 C10F900 Type 2 diabetes mellitus without complication 
 C10F911 Type II diabetes mellitus without complication 
 C10FA00 Type 2 diabetes mellitus with mononeuropathy 
 C10FA11 Type II diabetes mellitus with mononeuropathy 
 C10FB00 Type 2 diabetes mellitus with polyneuropathy 
 C10FB11 Type II diabetes mellitus with polyneuropathy 
 C10FC00 Type 2 diabetes mellitus with nephropathy 
 C10FC11 Type II diabetes mellitus with nephropathy 
 C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma 
 C10FD11 Type II diabetes mellitus with hypoglycaemic coma 
 C10FE00 Type 2 diabetes mellitus with diabetic cataract 
 C10FE11 Type II diabetes mellitus with diabetic cataract 
 C10FG00 Type 2 diabetes mellitus with arthropathy 
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 C10FG11 Type II diabetes mellitus with arthropathy 
 C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy 
 C10FH11 Type II diabetes mellitus with neuropathic arthropathy 
 C10FJ00 Insulin treated Type 2 diabetes mellitus 
 C10FJ11 Insulin treated Type II diabetes mellitus 
 C10FK00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
 C10FK11 Hyperosmolar non-ketotic state in type II diabetes mellitus 
 C10FL00 Type 2 diabetes mellitus with persistent proteinuria 
 C10FL11 Type II diabetes mellitus with persistent proteinuria 
 C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria 
 C10FM11 Type II diabetes mellitus with persistent microalbuminuria 
 C10FN00 Type 2 diabetes melli 
   
Hypertension G2...00 Hypertensive disease 
 G2...11 BP - hypertensive disease 
 G20..00 Essential hypertension 
 G20..11 High blood pressure 
 G20..12 Primary hypertension 
 G200.00 Malignant essential hypertension 
 G201.00 Benign essential hypertension 
 G202.00 Systolic hypertension 
 G203.00 Diastolic hypertension 
 G20z.00 Essential hypertension NOS 
 G20z.11 Hypertension NOS 
 G24..00 Secondary hypertension 
 G240.00 Secondary malignant hypertension 
 G240000 Secondary malignant renovascular hypertension 
 G240z00 Secondary malignant hypertension NOS 
 G241.00 Secondary benign hypertension 
 G241000 Secondary benign renovascular hypertension 
 G241z00 Secondary benign hypertension NOS 
 G244.00 Hypertension secondary to endocrine disorders 
 G24z.00 Secondary hypertension NOS 
 G24z000 Secondary renovascular hypertension NOS 
 G24z100 Hypertension secondary to drug 
 G24zz00 Secondary hypertension NOS 
 G25..00 Stage 1 hypertension (NICE - Nat Ins for Hth Clin Excl 2011) 
 G25..11 Stage 1 hypertension 
 G250.00 Stage 1 hyperten (NICE 2011) without evidence end organ damage 
 G251.00 Stage 1 hyperten (NICE 2011) with evidence end organ damage 
 G26..00 Severe hypertension (Nat Inst for Health Clinical Ex 2011) 
 G26..11 Severe hypertension 
 G27..00 Hypertension resistant to drug therapy 
 G28..00 Stage 2 hypertension (NICE - Nat Ins for Hth Clin Excl 2011) 
 Gyu2000 [X]Other secondary hypertension 
 Gyu2100 [X]Hypertension secondary to other renal disorders 
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Hyperlipidaemia 81048998 Atorvastatin 20mg chewable tablets sugar free 
 81051998 Atorvastatin 10mg chewable tablets sugar free 
 83099998 Simvastatin 40mg/5ml oral suspension sugar free 
 82655998 Nicotinic acid & laropiprant 1g+20mg tablets 
 83030998 Simvastatin 80mg tablets 
 81050998 Atorvastatin 10mg chewable tablets sugar free 
 84268998 Colesevelam 625mg tablets 
 84267998 Colesevelam 625mg tablets 
 83594998 Nicotinic acid 1g / laropiprant 20mg modified-release tablets 
 79254979 Simvastatin 20mg/5ml oral suspension sugar free 
 83188998 Bezafibrate 200mg tablets 
 83187998 Bezafibrate 400mg modified-release tablets 
 81049998 Atorvastatin 20mg chewable tablets sugar free 
 82141978 Eicosapentaenoic acid 460mg / Docosahexaenoic acid 380mg 
capsules 
 87853998 Nicotinic acid 1g modified-release tablets 
 87852998 Nicotinic acid 500mg modified release tablets 
 89154996 Cerivastatin 300microgram tablets 
 86791998 Simvastatin 80mg / Ezetimibe 10mg tablets 
 87854998 Nicotinic acid 750mg modified-release tablets 
 89153996 Cerivastatin sodium 300mcg tablets 
 88298997 Fenofibrate micronised 267mg capsules 
 88534998 Rosuvastatin 10mg tablets 
 86794998 Simvastatin 80mg / Ezetimibe 10mg tablets 
 86510979 Ispaghula husk 3.5g sugar free granules 
 87025998 Bezafibrate 400mg modified-release tablets 
 87418998 Simvastatin 10mg tablets 
 87918998 Simvastatin 10mg tablets 
 89401998 Bezafibrate 400mg modified-release tablets 
 87917998 Simvastatin 20mg tablets 
 89089998 Bezafibrate 400mg modified release tablets 
 87373998 Simvastatin 10mg tablets 
 87760998 Colestipol 5g granules sachets sugar free 
 86798998 Simvastatin 20mg / Ezetimibe 10mg tablets 
 88297996 Fenofibrate micronised 267mg capsules 
 87848998 Nicotinic acid pack 
 86796998 Simvastatin 40mg / Ezetimibe 10mg tablets 
 87849998 Nicotinic acid 375mg + 500mg + 750mg modified-release tablet 
 87850998 Nicotinic acid 1g modified release tablets 
 87851998 Nicotinic acid 750mg modified release tablets 
 86797998 Simvastatin 20mg / Ezetimibe 10mg tablets 
 87916998 Simvastatin 40mg tablets 
 89306996 Atorvastatin 40mg tablets 
 89311998 Atorvastatin 10mg tablets 
 89617998 Ispaghula husk 3.5g sugar free granules 
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 89154997 Cerivastatin 200microgram tablets 
 86795998 Simvastatin 40mg / Ezetimibe 10mg tablets 
 89311997 Atorvastatin 20mg tablets 
 89306998 Atorvastatin 10mg tablets 
 89311996 Atorvastatin 40mg tablets 
 88298996 Fenofibrate micronised 200mg capsules 
 86788998 Simvastatin 40mg / Ezetimibe 10mg tablets 
 86789998 Simvastatin 20mg / Ezetimibe 10mg tablets 
 89153998 Cerivastatin sodium 100mcg tablets 
 86787998 Simvastatin 80mg / Ezetimibe 10mg tablets 
 89154998 Cerivastatin 100microgram tablets 
 88297998 Fenofibrate micronised 67mg capsules 
 86467998 Rosuvastatin 5mg tablets 
 89285979 Nicotinic acid 500mg modified release tablets 
 89800998 Eicosapentaenoic acid 460mg / Docosahexaenoic acid 380mg 
capsules 
 89284979 Nicotinic acid 750mg modified release tablets 
 88298998 Fenofibrate micronised 67mg capsules 
 88297997 Fenofibrate micronised 200mg capsules 
 89306997 Atorvastatin 20mg tablets 
 87855998 Nicotinic acid 500mg modified-release tablets 
 89283979 Nicotinic acid 1g modified release tablets 
 89153997 Cerivastatin sodium 200mcg tablets 
 86468998 Rosuvastatin 5mg tablets 
 92447998 Cerivastatin sodium 400mcg tablets 
 90973998 Rosuvastatin 20mg tablets 
 93619998 Simvastatin 10mg tablets 
 92408998 Rosuvastatin 20mg tablets 
 93620996 Simvastatin 40mg tablets 
 92448997 Cerivastatin 800microgram tablets 
 92410998 Rosuvastatin 40mg tablets 
 93620997 Simvastatin 20mg tablets 
 93620998 Simvastatin 10mg tablets 
 93871990 Simvastatin 40mg tablets 
 92409998 Rosuvastatin 10mg tablets 
 93243996 Pravastatin 40mg tablets 
 91194998 Fluvastatin 80mg modified-release tablets 
 93010990 Colestyramine 4g oral powder sachets sugar free 
 92549990 Fenofibrate micronised 200mg capsules 
 93244998 Pravastatin 10mg tablets 
 93244997 Pravastatin 20mg tablets 
 93244996 Pravastatin 40mg tablets 
 92539998 Rosuvastatin 40mg tablets 
 90310998 Atorvastatin 80mg tablets 
 93243997 Pravastatin 20mg tablets 
 92448998 Cerivastatin 400microgram tablets 
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 94407990 Simvastatin 20mg tablets 
 93838990 Bezafibrate 200mg tablets 
 92471998 Simvastatin 80mg tablets 
 93851992 Colestipol 5g granules sachets sugar free 
 90309998 Atorvastatin 80mg tablets 
 92460998 Fenofibrate micronised 160mg tablets 
 91316998 Colestyramine sugar free powder 
 93243998 Pravastatin 10mg tablets 
 92292998 Ezetimibe 10mg tablets 
 92154990 Simvastatin 20mg/5ml oral suspension sugar free 
 93541998 Colestyramine 4g oral powder sachets 
 93542998 Colestyramine 4g oral powder sachets sugar free 
 92804997 Fluvastatin 40mg capsules 
 94189997 Fenofibrate micronised 200mg capsules 
 92293998 Ezetimibe 10mg tablets 
 90649998 Fenofibrate 200mg capsules 
 92805998 Fluvastatin 20mg capsules 
 92804998 Fluvastatin 20mg capsules 
 92805997 Fluvastatin 40mg capsules 
 93619996 Simvastatin 40mg tablets 
 92220998 Simvastatin 80mg tablets 
 90653998 Colestyramine 4g oral powder sachets sugar free 
 94188997 Fenofibrate micronised 200mg capsules 
 94112992 Cholestyramine 325 mg cap 
 94188998 Fenofibrate 100mg capsule 
 94189998 Fenofibrate 100mg capsules 
 92804996 Fluvastatin 80mg modified-release tablets 
 93619997 Simvastatin 20mg tablets 
 95480990 Simvastatin 10mg tablets 
 95479990 Simvastatin 20mg tablets 
 95952997 Bezafibrate 400mg modified-release tablets 
 95550990 Simvastatin 20mg tablets 
 95551990 Simvastatin 10mg tablets 
 94925998 Eicosapentaenoic acid 170mg / Docosahexaenoic acid 115mg 
capsules 
 95478990 Simvastatin 40mg tablets 
 95471990 Simvastatin 40mg tablets 
 95475990 Simvastatin 20mg tablets 
 94799998 Fenofibrate micronised 160mg tablets 
 96295997 Gemfibrozil 600mg tablets 
 95474990 Simvastatin 40mg tablets 
 95472990 Simvastatin 20mg tablets 
 95451990 Simvastatin 10mg tablets 
 95549990 Simvastatin 40mg tablets 
 96295998 Gemfibrozil 300mg capsules 
 94927990 Simvastatin 80mg tablets 
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 94827992 Colestyramine 4g oral powder sachets 
 95501990 Simvastatin 40mg tablets 
 94782990 Pravastatin 20mg tablets 
 95185990 Simvastatin 80mg tablets 
 95494990 Simvastatin 20mg tablets 
 94605998 Colestipol 5g granules sachets sugar free 
 95495990 Simvastatin 10mg tablets 
 94851990 Pravastatin 10mg tablets 
 95500990 Simvastatin 80mg tablets 
 94830990 Pravastatin 20mg tablets 
 95502990 Simvastatin 20mg tablets 
 97078998 Fish oil concentrate 1g capsules 
 96685990 Bezafibrate 400mg modified-release tablets 
 96685989 Bezafibrate 200mg tablets 
 97377979 Cerivastatin sodium 300mcg tablets 
 94831990 Pravastatin 10mg tablets 
 97078997 Fish oil concentrate oral liquid 
 94661998 Colestipol 5g granules sachets sugar free 
 95482990 Simvastatin 20mg tablets 
 95483990 Simvastatin 10mg tablets 
 95486990 Simvastatin 40mg tablets 
 95508990 Simvastatin 10mg tablets 
 95487990 Simvastatin 20mg tablets 
 95952998 Bezafibrate 200mg tablets 
 97078996 Fish oil concentrate oral emulsion 
 94850990 Pravastatin 20mg tablets 
 94849990 Pravastatin 40mg tablets 
 94662998 Colestipol 5g granules sachets sugar free 
 95493990 Simvastatin 40mg tablets 
 95847990 Colestyramine 4g oral powder sachets sugar free 
 95098992 Hexopal 200 mg tab 
 97455979 Pravastatin 10mg tablets 
 95481990 Simvastatin 40mg tablets 
 94661997 Colestipol 5g granules sachets sugar free 
 97430979 Fluvastatin 20mg capsules 
 95805998 Bezafibrate 400mg modified release tablets 
 95405990 Simvastatin 40mg tablets 
 94789990 Pravastatin 10mg tablets 
 95401998 Probucol 250mg tablet 
 97247997 Gemfibrozil 600mg tablets 
 97247998 Gemfibrozil 300mg capsules 
 96134990 Colestyramine 4g oral powder sachets 
 95278990 Simvastatin 20mg tablets 
 95277990 Simvastatin 40mg tablets 
 95372990 Simvasta 
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Table S2 Overview of codes used to define each cardiovascular disease endpoints 
Endpoint THIN 
READ 
Codes 
Description 
   
Coronary heart 
disease 
G3...00 Ischaemic heart disease 
 G3...11 Arteriosclerotic heart disease 
 G3...12 Atherosclerotic heart disease 
 G3...13 IHD - Ischaemic heart disease 
 G30..00 Acute myocardial infarction 
 G30..11 Attack - heart 
 G30..12 Coronary thrombosis 
 G30..13 Cardiac rupture following myocardial infarction (MI) 
 G30..14 Heart attack 
 G30..15 MI - acute myocardial infarction 
 G30..16 Thrombosis - coronary 
 G30..17 Silent myocardial infarction 
 G300.00 Acute anterolateral infarction 
 G301.00 Other specified anterior myocardial infarction 
 G301000 Acute anteroapical infarction 
 G301100 Acute anteroseptal infarction 
 G301z00 Anterior myocardial infarction NOS 
 G302.00 Acute inferolateral infarction 
 G303.00 Acute inferoposterior infarction 
 G304.00 Posterior myocardial infarction NOS 
 G305.00 Lateral myocardial infarction NOS 
 G306.00 True posterior myocardial infarction 
 G307.00 Acute subendocardial infarction 
 G307000 Acute non-Q wave infarction 
 G307100 Acute non-ST segment elevation myocardial infarction 
 G308.00 Inferior myocardial infarction NOS 
 G309.00 Acute Q-wave infarct 
 G30A.00 Mural thrombosis 
 G30B.00 Acute posterolateral myocardial infarction 
 G30X.00 Acute transmural myocardial infarction of unspecif site 
 G30X000 Acute ST segment elevation myocardial infarction 
 G30y.00 Other acute myocardial infarction 
 G30y000 Acute atrial infarction 
 G30y100 Acute papillary muscle infarction 
 G30y200 Acute septal infarction 
 G30yz00 Other acute myocardial infarction NOS 
 G30z.00 Acute myocardial infarction NOS 
 G31..00 Other acute and subacute ischaemic heart disease 
 G310.00 Postmyocardial infarction syndrome 
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 G310.11 Dressler's syndrome 
 G311.00 Preinfarction syndrome 
 G311.11 Crescendo angina 
 G311.12 Impending infarction 
 G311.13 Unstable angina 
 G311.14 Angina at rest 
 G311000 Myocardial infarction aborted 
 G311011 MI - myocardial infarction aborted 
 G311100 Unstable angina 
 G311200 Angina at rest 
 G311300 Refractory angina 
 G311400 Worsening angina 
 G311500 Acute coronary syndrome 
 G311z00 Preinfarction syndrome NOS 
 G312.00 Coronary thrombosis not resulting in myocardial infarction 
 G31y.00 Other acute and subacute ischaemic heart disease 
 G31y000 Acute coronary insufficiency 
 G31y100 Microinfarction of heart 
 G31y200 Subendocardial ischaemia 
 G31y300 Transient myocardial ischaemia 
 G31yz00 Other acute and subacute ischaemic heart disease NOS 
 G32..00 Old myocardial infarction 
 G32..11 Healed myocardial infarction 
 G32..12 Personal history of myocardial infarction 
 G33..00 Angina pectoris 
 G330.00 Angina decubitus 
 G330000 Nocturnal angina 
 G330z00 Angina decubitus NOS 
 G331.00 Prinzmetal's angina 
 G331.11 Variant angina pectoris 
 G332.00 Coronary artery spasm 
 G33z.00 Angina pectoris NOS 
 G33z000 Status anginosus 
 G33z100 Stenocardia 
 G33z200 Syncope anginosa 
 G33z300 Angina on effort 
 G33z400 Ischaemic chest pain 
 G33z500 Post infarct angina 
 G33z600 New onset angina 
 G33z700 Stable angina 
 G33zz00 Angina pectoris NOS 
 G34..00 Other chronic ischaemic heart disease 
 G340.00 Coronary atherosclerosis 
 G340.11 Triple vessel disease of the heart 
 G340.12 Coronary artery disease 
 G340000 Single coronary vessel disease 
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 G340100 Double coronary vessel disease 
 G341.00 Aneurysm of heart 
 G341.11 Cardiac aneurysm 
 G341000 Ventricular cardiac aneurysm 
 G341100 Other cardiac wall aneurysm 
 G341111 Mural cardiac aneurysm 
 G341200 Aneurysm of coronary vessels 
 G341300 Acquired atrioventricular fistula of heart 
 G341z00 Aneurysm of heart NOS 
 G342.00 Atherosclerotic cardiovascular disease 
 G343.00 Ischaemic cardiomyopathy 
 G344.00 Silent myocardial ischaemia 
 G34y.00 Other specified chronic ischaemic heart disease 
 G34y000 Chronic coronary insufficiency 
 G34y100 Chronic myocardial ischaemia 
 G34yz00 Other specified chronic ischaemic heart disease NOS 
 G34z.00 Other chronic ischaemic heart disease NOS 
 G34z000 Asymptomatic coronary heart disease 
 G35..00 Subsequent myocardial infarction 
 G350.00 Subsequent myocardial infarction of anterior wall 
 G351.00 Subsequent myocardial infarction of inferior wall 
 G353.00 Subsequent myocardial infarction of other sites 
 G35X.00 Subsequent myocardial infarction of unspecified site 
 G36..00 Certain current complication follow acute myocardial infarct 
 G360.00 Haemopericardium/current comp folow acut myocard infarct 
 G361.00 Atrial septal defect/curr comp folow acut myocardal infarct 
 G362.00 Ventric septal defect/curr comp fol acut myocardal infarctn 
 G363.00 Ruptur cardiac wall w'out haemopericard/cur comp fol ac MI 
 G364.00 Ruptur chordae tendinae/curr comp fol acute myocard infarct 
 G365.00 Rupture papillary muscle/curr comp fol acute myocard infarct 
 G366.00 Thrombosis atrium,auric append&vent/curr comp foll acute MI 
 G37..00 Cardiac syndrome X 
 G38..00 Postoperative myocardial infarction 
 G380.00 Postoperative transmural myocardial infarction anterior wall 
 G381.00 Postoperative transmural myocardial infarction inferior wall 
 G382.00 Postoperative transmural myocardial infarction other sites 
 G383.00 Postoperative transmural myocardial infarction unspec site 
 G384.00 Postoperative subendocardial myocardial infarction 
 G38z.00 Postoperative myocardial infarction, unspecified 
 G39..00 Coronary microvascular disease 
 G3y..00 Other specified ischaemic heart disease 
 G3z..00 Ischaemic heart disease NOS 
 Gyu3.00 [X]Ischaemic heart diseases 
 Gyu3000 [X]Other forms of angina pectoris 
 Gyu3100 [X]Other current complications following acute myocard infarct 
 Gyu3200 [X]Other forms of acute ischaemic heart disease 
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 Gyu3300 [X]Other forms of chronic ischaemic heart disease 
 Gyu3400 [X]Acute transmural myocardial infarction of unspecif site 
 Gyu3500 [X]Subsequent myocardial infarction of other sites 
 Gyu3600 [X]Subsequent myocardial infarction of unspecified site 
   
Cerebrovascular 
disease 
  
 G6...00 Cerebrovascular disease 
 G60..00 Subarachnoid haemorrhage 
 G600.00 Ruptured berry aneurysm 
 G601.00 Subarachnoid haemorrhage from carotid siphon and bifurcation 
 G602.00 Subarachnoid haemorrhage from middle cerebral artery 
 G603.00 Subarachnoid haemorrhage from anterior communicating artery 
 G604.00 Subarachnoid haemorrhage from posterior communicating artery 
 G605.00 Subarachnoid haemorrhage from basilar artery 
 G606.00 Subarachnoid haemorrhage from vertebral artery 
 G60X.00 Subarachnoid haemorrh from intracranial artery, unspecif 
 G60z.00 Subarachnoid haemorrhage NOS 
 G61..00 Intracerebral haemorrhage 
 G61..11 CVA - cerebrovascular accid due to intracerebral haemorrhage 
 G61..12 Stroke due to intracerebral haemorrhage 
 G610.00 Cortical haemorrhage 
 G611.00 Internal capsule haemorrhage 
 G612.00 Basal nucleus haemorrhage 
 G613.00 Cerebellar haemorrhage 
 G614.00 Pontine haemorrhage 
 G615.00 Bulbar haemorrhage 
 G616.00 External capsule haemorrhage 
 G617.00 Intracerebral haemorrhage, intraventricular 
 G618.00 Intracerebral haemorrhage, multiple localized 
 G619.00 Lobar cerebral haemorrhage 
 G61X.00 Intracerebral haemorrhage in hemisphere, unspecified 
 G61X000 Left sided intracerebral haemorrhage, unspecified 
 G61X100 Right sided intracerebral haemorrhage, unspecified 
 G61z.00 Intracerebral haemorrhage NOS 
 G62..00 Other and unspecified intracranial haemorrhage 
 G620.00 Extradural haemorrhage - nontraumatic 
 G621.00 Subdural haemorrhage - nontraumatic 
 G622.00 Subdural haematoma - nontraumatic 
 G623.00 Subdural haemorrhage NOS 
 G62z.00 Intracranial haemorrhage NOS 
 G63..00 Precerebral arterial occlusion 
 G63..11 Infarction - precerebral 
 G63..12 Stenosis of precerebral arteries 
 G630.00 Basilar artery occlusion 
 G631.00 Carotid artery occlusion 
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 G631.11 Stenosis, carotid artery 
 G631.12 Thrombosis, carotid artery 
 G632.00 Vertebral artery occlusion 
 G633.00 Multiple and bilateral precerebral arterial occlusion 
 G634.00 Carotid artery stenosis 
 G63y.00 Other precerebral artery occlusion 
 G63y000 Cerebral infarct due to thrombosis of precerebral arteries 
 G63y100 Cerebral infarction due to embolism of precerebral arteries 
 G63z.00 Precerebral artery occlusion NOS 
 G64..00 Cerebral arterial occlusion 
 G64..11 CVA - cerebral artery occlusion 
 G64..12 Infarction - cerebral 
 G64..13 Stroke due to cerebral arterial occlusion 
 G640.00 Cerebral thrombosis 
 G640000 Cerebral infarction due to thrombosis of cerebral arteries 
 G641.00 Cerebral embolism 
 G641.11 Cerebral embolus 
 G641000 Cerebral infarction due to embolism of cerebral arteries 
 G64z.00 Cerebral infarction NOS 
 G64z.11 Brainstem infarction NOS 
 G64z.12 Cerebellar infarction 
 G64z000 Brainstem infarction 
 G64z100 Wallenberg syndrome 
 G64z111 Lateral medullary syndrome 
 G64z200 Left sided cerebral infarction 
 G64z300 Right sided cerebral infarction 
 G64z400 Infarction of basal ganglia 
 G65..00 Transient cerebral ischaemia 
 G65..11 Drop attack 
 G65..12 Transient ischaemic attack 
 G65..13 Vertebro-basilar insufficiency 
 G650.00 Basilar artery syndrome 
 G650.11 Insufficiency - basilar artery 
 G651.00 Vertebral artery syndrome 
 G651000 Vertebro-basilar artery syndrome 
 G652.00 Subclavian steal syndrome 
 G653.00 Carotid artery syndrome hemispheric 
 G654.00 Multiple and bilateral precerebral artery syndromes 
 G655.00 Transient global amnesia 
 G656.00 Vertebrobasilar insufficiency 
 G657.00 Carotid territory transient ischaemic attack 
 G65y.00 Other transient cerebral ischaemia 
 G65z.00 Transient cerebral ischaemia NOS 
 G65z000 Impending cerebral ischaemia 
 G65z100 Intermittent cerebral ischaemia 
 G65zz00 Transient cerebral ischaemia NOS 
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 G66..00 Stroke and cerebrovascular accident unspecified 
 G66..11 CVA unspecified 
 G66..12 Stroke unspecified 
 G66..13 CVA - Cerebrovascular accident unspecified 
 G660.00 Middle cerebral artery syndrome 
 G661.00 Anterior cerebral artery syndrome 
 G662.00 Posterior cerebral artery syndrome 
 G663.00 Brain stem stroke syndrome 
 G664.00 Cerebellar stroke syndrome 
 G665.00 Pure motor lacunar syndrome 
 G666.00 Pure sensory lacunar syndrome 
 G667.00 Left sided CVA 
 G668.00 Right sided CVA 
 G669.00 Cerebral palsy, not congenital or infantile, acute 
 G67..00 Other cerebrovascular disease 
 G670.00 Cerebral atherosclerosis 
 G670.11 Precerebral atherosclerosis 
 G671.00 Generalised ischaemic cerebrovascular disease NOS 
 G671000 Acute cerebrovascular insufficiency NOS 
 G671100 Chronic cerebral ischaemia 
 G671z00 Generalised ischaemic cerebrovascular disease NOS 
 G672.00 Hypertensive encephalopathy 
 G672.11 Hypertensive crisis 
 G673.00 Cerebral aneurysm, nonruptured 
 G673000 Dissection of cerebral arteries, nonruptured 
 G673100 Carotico-cavernous sinus fistula 
 G673200 Carotid artery dissection 
 G673300 Vertebral artery dissection 
 G674.00 Cerebral arteritis 
 G674000 Cerebral amyloid angiopathy 
 G675.00 Moyamoya disease 
 G676.00 Nonpyogenic venous sinus thrombosis 
 G676000 Cereb infarct due cerebral venous thrombosis, nonpyogenic 
 G677.00 Occlusion/stenosis cerebral arts not result cerebral infarct 
 G677000 Occlusion and stenosis of middle cerebral artery 
 G677100 Occlusion and stenosis of anterior cerebral artery 
 G677200 Occlusion and stenosis of posterior cerebral artery 
 G677300 Occlusion and stenosis of cerebellar arteries 
 G677400 Occlusion+stenosis of multiple and bilat cerebral arteries 
 G678.00 Cereb autosom dominant arteriop subcort infarcts leukoenceph 
 G679.00 Small vessel cerebrovascular disease 
 G67A.00 Cerebral vein thrombosis 
 G67B.00 Reversible cerebral vasoconstriction syndrome 
 G67B.11 Call-Fleming syndrome 
 G67y.00 Other cerebrovascular disease OS 
 G67z.00 Other cerebrovascular disease NOS 
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 G68..00 Late effects of cerebrovascular disease 
 G680.00 Sequelae of subarachnoid haemorrhage 
 G681.00 Sequelae of intracerebral haemorrhage 
 G682.00 Sequelae of other nontraumatic intracranial haemorrhage 
 G683.00 Sequelae of cerebral infarction 
 G68W.00 Sequelae/other + unspecified cerebrovascular diseases 
 G68X.00 Sequelae of stroke,not specfd as h'morrhage or infarction 
 G6y..00 Other specified cerebrovascular disease 
 G6z..00 Cerebrovascular disease NOS 
 Gyu6.00 [X]Cerebrovascular diseases 
 Gyu6000 [X]Subarachnoid haemorrhage from other intracranial arteries 
 Gyu6100 [X]Other subarachnoid haemorrhage 
 Gyu6200 [X]Other intracerebral haemorrhage 
 Gyu6300 [X]Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
 Gyu6400 [X]Other cerebral infarction 
 Gyu6500 [X]Occlusion and stenosis of other precerebral arteries 
 Gyu6600 [X]Occlusion and stenosis of other cerebral arteries 
 Gyu6700 [X]Other specified cerebrovascular diseases 
 Gyu6C00 [X]Sequelae of stroke;not specfd as h'morrhage or infarction 
 Gyu6D00 [X]Sequelae/other unspecified cerebrovascular diseases 
 Gyu6E00 [X]Subarachnoid haemorrh from intracranial artery, unspecif 
 Gyu6F00 [X]Intracerebral haemorrhage in hemisphere, unspecified 
 Gyu6G00 [X]Cereb infarct due unsp occlus/stenos precerebr arteries 
 G6W..00 Cereb infarct due unsp occlus/stenos precerebr arteries 
 G6X..00 Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
Heart Failure   
 1O1..00 Heart failure confirmed 
 2JZ..00 On optimal heart failure therapy 
 662f.00 New York Heart Association classification - class I 
 662g.00 New York Heart Association classification - class II 
 662h.00 New York Heart Association classification - class III 
 662i.00 New York Heart Association classification - class IV 
 8B29.00 Cardiac failure therapy 
 G58..00 Heart failure 
 G58..11 Cardiac failure 
 G580.00 Congestive heart failure 
 G580.11 Congestive cardiac failure 
 G580.14 Biventricular failure 
 G580000 Acute congestive heart failure 
 G580100 Chronic congestive heart failure 
 G580200 Decompensated cardiac failure 
 G580300 Compensated cardiac failure 
 G580400 Congestive heart failure due to valvular disease 
 G581.00 Left ventricular failure 
 G581.11 Asthma - cardiac 
 G581.13 Impaired left ventricular function 
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 G581000 Acute left ventricular failure 
 G582.00 Acute heart failure 
 G583.00 Heart failure with normal ejection fraction 
 G583.11 HFNEF - heart failure with normal ejection fraction 
 G583.12 Heart failure with preserved ejection fraction 
 G58z.00 Heart failure NOS 
 G58z.12 Cardiac failure NOS 
 G5y4z00 Post cardiac operation heart failure NOS 
 661M500 Heart failure self-management plan agreed 
 661N500 Heart failure self-management plan review 
 662p.00 Heart failure 6 month review 
 662T.00 Congestive heart failure monitoring 
 662W.00 Heart failure annual review 
 679W100 education about deteriorating heart failure 
 8H2S.00 Admit heart failure emergency 
 8HBE.00 Heart failure follow-up 
 8HTL000 Referral to rapid access heart failure clinic 
 G232.00 Hypertensive heart&renal dis wth (congestive) heart failure 
 G234.00 Hyperten heart&renal dis+both(congestv)heart and renal fail 
 G581.12 Pulmonary oedema - acute 
 G58z.11 Weak heart 
 SP11111 Heart failure as a complication of care 
 SP11200 Cardiorespiratory failure as a complication of care 
 G554000 Congestive cardiomyopathy 
Peripheral 
vascular disease 
  
 C108G00 Insulin dependent diab mell with peripheral angiopathy 
 C108G11 Type I diabetes mellitus with peripheral angiopathy 
 C108G12 Type 1 diabetes mellitus with peripheral angiopathy 
 C109F11 Type II diabetes mellitus with peripheral angiopathy 
 C109F12 Type 2 diabetes mellitus with peripheral angiopathy 
 C10EG00 Type 1 diabetes mellitus with peripheral angiopathy 
 C10EG11 Type I diabetes mellitus with peripheral angiopathy 
 C10EG12 Insulin dependent diab mell with peripheral angiopathy 
 C10FF00 Type 2 diabetes mellitus with peripheral angiopathy 
 C10FF11 Type II diabetes mellitus with peripheral angiopathy 
 G711.00 Thoracic aortic aneurysm which has ruptured 
 G711.11 Ruptured thoracic aortic aneurysm 
 G712.00 Thoracic aortic aneurysm without mention of rupture 
 G713.00 Abdominal aortic aneurysm which has ruptured 
 G713.11 Ruptured abdominal aortic aneurysm 
 G713000 Ruptured suprarenal aortic aneurysm 
 G714.00 Abdominal aortic aneurysm without mention of rupture 
 G714.11 AAA - Abdominal aortic aneurysm without mention of rupture 
 G714000 Juxtarenal aortic aneurysm 
 G714200 Infrarenal abdominal aortic aneurysm 
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 G714300 Aneurysm of suprarenal aorta 
 G715.00 Ruptured aortic aneurysm NOS 
 G715000 Thoracoabdominal aortic aneurysm, ruptured 
 G716.00 Aortic aneurysm without mention of rupture NOS 
 G716000 Thoracoabdominal aortic aneurysm, without mention of rupture 
 G718.00 Leaking abdominal aortic aneurysm 
 G71z.00 Aortic aneurysm NOS 
 G72..00 Other aneurysm 
 G720.00 Aneurysm of artery of arm 
 G720000 Aneurysm of brachial artery 
 G720100 Aneurysm of radial artery 
 G720200 Aneurysm of ulnar artery 
 G720z00 Aneurysm of arm artery NOS 
 G721.00 Aneurysm of renal artery 
 G721000 Acquired renal artery aneurysm 
 G722.00 Aneurysm of iliac artery 
 G722000 Aneurysm of common iliac artery 
 G722100 Aneurysm of external iliac artery 
 G722200 Aneurysm of internal iliac artery 
 G722z00 Aneurysm of iliac artery NOS 
 G723.00 Aneurysm of leg artery 
 G723000 Aneurysm of femoral artery 
 G723100 Aneurysm of popliteal artery 
 G723200 Aneurysm of anterior tibial artery 
 G723300 Aneurysm of dorsalis pedis artery 
 G723400 Aneurysm of posterior tibial artery 
 G723500 Ruptured popliteal artery aneurysm 
 G723600 Post radiological femoral false aneurysm 
 G723z00 Aneurysm of leg artery NOS 
 G73..00 Other peripheral vascular disease 
 G731.00 Thromboangiitis obliterans 
 G731000 Buerger's disease 
 G734.00 Peripheral arterial disease 
 G73y.00 Other specified peripheral vascular disease 
 G73y000 Diabetic peripheral angiopathy 
 G73z.00 Peripheral vascular disease NOS 
 G73z000 Intermittent claudication 
 G73zz00 Peripheral vascular disease NOS 
 G740.13 Leriche's syndrome 
 G76z100 Femoral artery occlusion 
 G76z200 Popliteal artery occlusion 
 Gyu7400 [X]Other specified peripheral vascular diseases 
 Gyu7A00 [X]Peripheral angiopathy in diseases classified elsewhere 
 G73..11 Peripheral ischaemic vascular disease 
 G73..12 Ischaemia of legs 
 G73..13 Peripheral ischaemia 
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 C107.11 Diabetes mellitus with gangrene 
 C107.12 Diabetes with gangrene 
 C107000 Diabetes mellitus, juvenile +peripheral circulatory disorder 
 C107100 Diabetes mellitus, adult, + peripheral circulatory disorder 
 C107200 Diabetes mellitus, adult with gangrene 
 C107300 IDDM with peripheral circulatory disorder 
 C107400 NIDDM with peripheral circulatory disorder 
 C107y00 Other specified diabetes mellitus with periph circ comps 
 C107z00 Diabetes mellitus NOS with peripheral circulatory disorder 
 C108600 Insulin dependent diabetes mellitus with gangrene 
 C108611 Type I diabetes mellitus with gangrene 
 C108612 Type 1 diabetes mellitus with gangrene 
 C109500 Non-insulin dependent diabetes mellitus with gangrene 
 C109511 Type II diabetes mellitus with gangrene 
 C109512 Type 2 diabetes mellitus with gangrene 
 C10E600 Type 1 diabetes mellitus with gangrene 
 C10E611 Type I diabetes mellitus with gangrene 
 C10E612 Insulin dependent diabetes mellitus with gangrene 
 C10F500 Type 2 diabetes mellitus with gangrene 
 C10F511 Type II diabetes mellitus with gangrene 
 G71..00 Aortic aneurysm 
 G710.00 Dissecting aortic aneurysm 
 G72y.00 Aneurysm of other artery 
 G72y000 Aneurysm of common carotid art 
 G72y100 Aneurysm of external carotid artery 
 G72y200 Aneurysm of internal carotid artery 
 G72y300 Aneurysm of neck artery NOS 
 G72y400 Aneurysm of subclavian artery 
 G72y500 Aneurysm of splenic artery 
 G72y600 Aneurysm of axillary artery 
 G72y700 Aneurysm of coeliac artery 
 G72y800 Aneurysm of superior mesenteric artery 
 G72y900 Aneurysm of inferior mesenteric artery 
 G72yA00 Aneurysm of hepatic artery 
 G72yB00 Aneurysm of other visceral artery 
 G72z.00 Aneurysm NOS 
 G733.00 Ischaemic foot 
 G73y100 Peripheral angiopathic disease EC NOS 
 G73z011 Claudication 
 G73z012 Vascular claudication 
 G73z100 Spasm of peripheral artery 
 G74..00 Arterial embolism and thrombosis 
 G74..11 Arterial embolus and thrombosis 
 G74..12 Thrombosis - arterial 
 G74..13 Arterial embolic and thrombotic occlusion 
 G740.00 Embolism and thrombosis of the abdominal aorta 
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Table S3 Distribution of body size phenotypes and metabolic status in the Health Improvement 
Network (N=3,495,777) 
 
Body size phenotype and metabolic status N (%) 
Underweight, 0 metabolic abnormalities 86,847 2.5 
Underweight, 1 metabolic abnormalities 5,758 0.2 
Underweight, 2 metabolic abnormalities 1,259 0.0 
Underweight, 3 metabolic abnormalities 165 0.0 
Normal weight, 0 metabolic abnormalities 1,318,516 37.7 
Normal weight, 1 metabolic abnormality 118,684 3.4 
Normal weight, 2 metabolic abnormalities 36,808 1.1 
Normal weight, 3 metabolic abnormalities 6,218 0.2 
Overweight, 0 metabolic abnormalities 899,471 25.7 
Overweight, 1 metabolic abnormality 171,412 4.9 
Overweight, 2 metabolic abnormalities 71,439 2.0 
Overweight, 3 metabolic abnormalities 16,494 0.5 
Obese, 0 metabolic abnormalities 517,444 14.8 
Obese, 1 metabolic abnormality 148,190 4.24 
Obese, 2 metabolic abnormalities 70,278 2.01 
Obese, 3 metabolic abnormalities 26,794 0.77 
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Table S4 Incidence rate of coronary heart disease by body size phenotype and metabolic status 
 
  
 # patients # patients with event # patient years of 
follow up 
Incidence rate/1000 y 
Underweight, 0 metabolic abnormalities 86,847 439 382367.07 1.15 
Underweight, ≥ 1 metabolic abnormality 7,182 208 30594.24 6.80 
Normal weight, 0 metabolic abnormalities 1,318,516 9895 6661783.30 1.49 
Normal weight, 1 metabolic abnormality 118,684 4783 684828.15 6.98 
Normal weight, 2 metabolic abnormalities 36,808 1631 190514.26 8.56 
Normal weight, 3 metabolic abnormalities 6,218 359 31149.97 11.52 
Overweight, 0 metabolic abnormalities 899,471 13056 4914040.90 2.66 
Overweight, 1 metabolic abnormality 171,412 7960 1047503.00 7.60 
Overweight, 2 metabolic abnormalities 71,439 3656 389450.18 9.39 
Overweight, 3 metabolic abnormalities 16,494 1018 89959.21 11.32 
Obese, 0 metabolic abnormalities 517,444 7526 2847791.80 2.64 
Obese, 1 metabolic abnormality 148,190 6127 916305.49 6.69 
Obese, 2 metabolic abnormalities 70,278 3324 382390.31 8.69 
Obese, 3 metabolic abnormalities 26,794 1564 140615.84 11.12 
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Table S5 Incidence rate of cerebrovascular disease by body size phenotype and metabolic status 
 
 # patients # patients with event # patient years of 
follow up 
Incidence rate/1000 y 
Underweight, 0 metabolic abnormalities 86,847 750 381629.72 1.97 
Underweight, ≥ 1 metabolic abnormality 7,182 390 30374.81 12.84 
Normal weight, 0 metabolic abnormalities 1,318,516 10918 6665697.30 1.64 
Normal weight, 1 metabolic abnormality 118,684 5628 687108.94 8.19 
Normal weight, 2 metabolic abnormalities 36,808 1706 191754.77 8.90 
Normal weight, 3 metabolic abnormalities 6,218 381 31396.80 12.13 
Overweight, 0 metabolic abnormalities 899,471 10097 4935219.40 2.05 
Overweight, 1 metabolic abnormality 171,412 7179 1058514.00 6.78 
Overweight, 2 metabolic abnormalities 71,439 3064 394740.39 7.76 
Overweight, 3 metabolic abnormalities 16,494 883 91070.76 9.70 
Obese, 0 metabolic abnormalities 517,444 5266 2861789.20 1.84 
Obese, 1 metabolic abnormality 148,190 4791 926935.57 5.17 
Obese, 2 metabolic abnormalities 70,278 2550 388122.06 6.57 
Obese, 3 metabolic abnormalities 26,794 1102 143326.81 7.69 
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Table S6 Incidence rate of heart failure by body size phenotype and metabolic status 
 # patients # patients with event # patient years of 
follow up 
Incidence rate/1000 y 
Underweight, 0 metabolic abnormalities 86,847 283 383187.38 0.74 
Underweight, ≥ 1 metabolic abnormality 7,182 158 30990.91 5.10 
Normal weight, 0 metabolic abnormalities 1,318,516 3555 6693309.60 0.53 
Normal weight, 1 metabolic abnormality 118,684 2381 699540.86 3.40 
Normal weight, 2 metabolic abnormalities 36,808 744 195390.05 3.81 
Normal weight, 3 metabolic abnormalities 6,218 169 32063.14 5.27 
Overweight, 0 metabolic abnormalities 899,471 3619 4961523.10 0.73 
Overweight, 1 metabolic abnormality 171,412 3457 1074562.70 3.22 
Overweight, 2 metabolic abnormalities 71,439 1514 400568.30 3.78 
Overweight, 3 metabolic abnormalities 16,494 463 92695.20 4.99 
Obese, 0 metabolic abnormalities 517,444 2813 2871691.70 0.98 
Obese, 1 metabolic abnormality 148,190 3330 2871691.70 3.57 
Obese, 2 metabolic abnormalities 70,278 1858 391089.97 4.75 
Obese, 3 metabolic abnormalities 26,794 910 144252.07 6.31 
  
  26 
Table S7 Incidence rate of peripheral vascular disease by body size phenotype and metabolic status 
 # patients # patients with event # patient years of 
follow up 
Incidence rate/1000 y 
Underweight, 0 metabolic abnormalities 86,847 283 383187.38 0.74 
Underweight, ≥ 1 metabolic abnormality 7,182 158 30990.91 5.10 
Normal weight, 0 metabolic abnormalities 1,318,516 3555 6693309.60 0.53 
Normal weight, 1 metabolic abnormality 118,684 2381 699540.86 3.40 
Normal weight, 2 metabolic abnormalities 36,808 744 195390.05 3.81 
Normal weight, 3 metabolic abnormalities 6,218 169 32063.14 5.27 
Overweight, 0 metabolic abnormalities 899,471 3619 4961523.10 0.73 
Overweight, 1 metabolic abnormality 171,412 3457 1074562.70 3.22 
Overweight, 2 metabolic abnormalities 71,439 1514 400568.30 3.78 
Overweight, 3 metabolic abnormalities 16,494 463 92695.20 4.99 
Obese, 0 metabolic abnormalities 517,444 2813 2871691.70 0.98 
Obese, 1 metabolic abnormality 148,190 3330 2871691.70 3.57 
Obese, 2 metabolic abnormalities 70,278 1858 391089.97 4.75 
Obese, 3 metabolic abnormalities 26,794 910 144252.07 6.31 
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Table S8 Sensitivity analysis results: Association between body size phenotype and metabolic status with coronary heart disease by sex and age 
Body size phenotype and metabolic status Sex 
HR (95% CI)* 
Age (years) 
HR (95% CI)† 
 Male Female <65 ≥ 65 
Underweight, 0 metabolic abnormalities 0.83(0.71-0.98) 0.99(0.88-1.11) 0.87(0.76-0.87) 0.88(0.78-1.00) 
Underweight, 1 or more metabolic abnormalities 1.05(0.78-1.41) 1.59(1.37-1.86) 1.73(1.31-1.73) 1.15(0.98-1.35) 
Normal weight, 0 metabolic abnormalities 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Normal weight, 1 metabolic abnormality 1.54(1.47-1.62) 1.73(1.63-1.83) 2.10(1.98-2.10) 1.23(1.17-1.29) 
Normal weight, 2 metabolic abnormalities 1.53(1.42-1.65) 1.90(1.75-2.06) 2.30(2.09-2.30) 1.27(1.19-1.36) 
Normal weight, 3 metabolic abnormalities 1.89(1.63-2.20) 2.55(2.19-2.97) 3.38(2.83-3.38) 1.56(1.37-1.78) 
Overweight, 0 metabolic abnormalities 1.26(1.22-1.31) 1.26(1.20-1.32) 1.40(1.35-1.40) 1.16(1.11-1.21) 
Overweight, 1 metabolic abnormality 1.68(1.61-1.75) 1.87(1.78-1.96) 2.21(2.11-2.21) 1.33(1.27-1.39) 
Overweight, 2 metabolic abnormalities 1.72(1.63-1.82) 2.17(2.03-2.31) 2.53(2.38-2.53) 1.38(1.30-1.45) 
Overweight, 3 metabolic abnormalities 2.00(1.84-2.17) 2.48(2.22-2.77) 3.11(2.81-3.11) 1.55(1.42-1.70) 
Obese, 0 metabolic abnormalities 1.46(1.40-1.52) 1.48(1.41-1.55) 1.72(1.66-1.72) 1.15(1.09-1.22) 
Obese, 1 metabolic abnormality 1.78(1.71-1.86) 2.04(1.94-2.16) 2.41(2.30-2.41) 1.36(1.29-1.43) 
Obese, 2 metabolic abnormalities 1.86(1.76-1.96) 2.40(2.24-2.56) 2.83(2.68-2.83) 1.40(1.31-1.49) 
Obese, 3 metabolic abnormalities 2.28(2.11-2.46) 2.90(2.66-3.16) 3.62(3.35-3.62) 1.65(1.52-1.79) 
HR= Hazard Ratio; CI= Confidence interval 
*Model adjusted for age, smoking status and social deprivation †Model adjusted for sex, smoking status and social deprivation 
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Table S9 Sensitivity analysis results: Association between body size phenotype and metabolic status with coronary heart disease using metabolic status derived from prescription records 
or measurement, different adjustments and exclusion of type 1 diabetes cases 
Body size phenotype and metabolic status Metabolic status 
derived from 
prescription 
records or 
measurement  
HR (95% CI)* 
HRT 
HR (95% CI) †§ 
Adjusted for 
oral 
contraceptives 
HR (95% CI)‡ § 
Excluded  
Type 1 DM 
cases* 
Never smoked 
HR (95% CI) || 
 
Underweight, 0 metabolic abnormalities 0.91(0.78-1.06) 0.99(0.88-1.11) 0.98(0.88-1.10) 0.92(0.84-1.01) 0.92(0.77-1.09) 
Underweight, 1 or more metabolic abnormalities 1.82(1.65-2.02) 1.60(1.37-1.86) 1.59(1.36-1.85) 1.46(1.27-1.68) 1.61(1.31-1.96) 
Normal weight, 0 metabolic abnormalities 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Normal weight, 1 metabolic abnormality 1.76(1.69-1.83) 1.73(1.63-1.83) 1.72(1.63-1.83) 1.64(1.58-1.70) 1.77(1.67-1.86) 
Normal weight, 2 metabolic abnormalities 2.24(2.13-2.36) 1.91(1.76-2.07) 1.90(1.75-2.05) 1.65(1.56-1.75) 1.95(1.79-2.12) 
Normal weight, 3 metabolic abnormalities 3.08(2.84-3.33) 2.57(2.21-2.99) 2.54(2.18-2.96) 2.03(1.80-2.27) 2.55(2.20-2.95) 
Overweight, 0 metabolic abnormalities 1.32(1.26-1.37) 1.26(1.20-1.31) 1.25(1.20-1.31) 1.30(1.26-1.33) 1.33(1.28-1.39) 
Overweight, 1 metabolic abnormality 2.07(1.99-2.16) 1.86(1.78-1.96) 1.86(1.77-1.95) 1.76(1.71-1.82) 1.91(1.83-2.00) 
Overweight, 2 metabolic abnormalities 2.46(2.35-2.58) 2.17(2.03-2.32) 2.16(2.02-2.30) 1.87(1.79-1.96) 2.22(2.09-2.36) 
Overweight, 3 metabolic abnormalities 3.18(2.99-3.37) 2.49(2.23-2.79) 2.47(2.21-2.76) 2.13(1.98-2.28) 2.60(2.36-2.87) 
Obese, 0 metabolic abnormalities 1.59(1.50-1.68) 1.49(1.42-1.56) 1.48(1.41-1.55) 1.50(1.45-1.54) 1.53(1.46-1.60) 
Obese, 1 metabolic abnormality 2.24(2.15-2.34) 2.05(1.94-2.16) 2.03(1.93-2.15) 1.92(1.85-1.99) 2.10(1.99-2.21) 
Obese, 2 metabolic abnormalities 2.61(2.50-2.73) 2.41(2.25-2.58) 2.38(2.23-2.55) 2.07(1.98-2.17) 2.46(2.31-2.63) 
Obese, 3 metabolic abnormalities 3.63(3.43-3.83) 2.92(2.68-3.18) 2.89(2.65-3.14) 2.50(2.36-2.65) 3.08(2.84-3.34) 
HR= Hazard Ratio; CI= Confidence interval; HRT= hormone replacement therapy 
*Model adjusted for age, sex, smoking status and social deprivation †Model adjusted for age, sex, smoking status, social deprivation and HRT 
‡Model adjusted for age, sex, smoking status, social deprivation and oral contraceptives 
§Women only 
||
 Model adjusted for age, sex, and social deprivation 
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Table S10 Sensitivity analysis results: Association between body size phenotype and metabolic status with cerebrovascular disease by sex and age 
Body size phenotype and metabolic status Sex 
HR (95% CI)* 
Age (years) 
HR (95% CI)† 
 Male Female <65 ≥ 65 
Underweight, 0 metabolic abnormalities 1.15(1.01-1.32) 1.23(1.12-1.34) 1.27(1.13-1.42) 1.11(1.00-1.22) 
Underweight, 1 or more metabolic abnormalities 1.99(1.59-2.48) 1.52(1.35-1.72) 2.79(2.23-3.49) 1.33(1.18-1.50) 
Normal weight, 0 metabolic abnormalities 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Normal weight, 1 metabolic abnormality 1.32(1.26-1.39) 1.41(1.35-1.47) 1.69(1.59-1.79) 1.19(1.14-1.24) 
Normal weight, 2 metabolic abnormalities 1.25(1.15-1.35) 1.34(1.25-1.43) 1.77(1.58-1.98) 1.11(1.04-1.18) 
Normal weight, 3 metabolic abnormalities 1.50(1.28-1.75) 1.73(1.52-1.97) 2.76(2.22-3.43) 1.34(1.20-1.50) 
Overweight, 0 metabolic abnormalities 0.96(0.92-0.99) 1.03(0.99-1.07) 1.05(1.01-1.09) 0.97(0.93-1.00) 
Overweight, 1 metabolic abnormality 1.21(1.16-1.27) 1.36(1.30-1.42) 1.57(1.49-1.65) 1.12(1.08-1.16) 
Overweight, 2 metabolic abnormalities 1.19(1.12-1.26) 1.44(1.35-1.53) 1.73(1.60-1.87) 1.11(1.05-1.17) 
Overweight, 3 metabolic abnormalities 1.40(1.26-1.55) 1.63(1.47-1.82) 1.99(1.73-2.28) 1.30(1.20-1.42) 
Obese, 0 metabolic abnormalities 1.01(0.96-1.07) 1.11(1.07-1.16) 1.20(1.15-1.25) 0.95(0.90-1.00) 
Obese, 1 metabolic abnormality 1.20(1.14-1.27) 1.39(1.32-1.45) 1.61(1.53-1.69) 1.09(1.04-1.14) 
Obese, 2 metabolic abnormalities 1.33(1.25-1.42) 1.51(1.43-1.61) 1.84(1.72-1.97) 1.18(1.11-1.25) 
Obese, 3 metabolic abnormalities 1.38(1.24-1.52) 1.75(1.61-1.90) 2.22(2.02-2.44) 1.23(1.13-1.34) 
HR= Hazard Ratio; CI= Confidence interval 
*Model adjusted for age, smoking status and social deprivation †Model adjusted for sex, smoking status and social deprivation 
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Table S11 Sensitivity analysis results: Association between body size phenotype and metabolic status with cerebrovascular disease using metabolic status derived from prescription 
records or measurement, different adjustments, exclusion of type 1 diabetes cases and inclusion of only those who never smoked cigarettes 
Body size phenotype and metabolic status Metabolic status 
derived from 
prescription 
records or 
measurement  
HR (95% CI)* 
HRT 
HR (95% CI) †§ 
Adjusted for 
oral 
contraceptives 
HR (95% CI)‡ § 
Excluded  
Type 1 DM cases* 
Never smoked 
HR (95% CI) || 
 
Underweight, 0 metabolic abnormalities 1.30(1.17-1.45) 1.23(1.13-1.35) 1.23(1.12-1.34) 1.20(1.11-1.29) 1.12(0.99-1.26) 
Underweight, 1 or more metabolic abnormalities 1.74(1.60-1.89) 1.53(1.35-1.72) 1.52(1.35-1.71) 1.56(1.40-1.75) 1.60(1.38-1.86) 
Normal weight, 0 metabolic abnormalities 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Normal weight, 1 metabolic abnormality 1.44(1.39-1.50) 1.41(1.35-1.47) 1.41(1.35-1.47) 1.36(1.32-1.41) 1.40(1.33-1.46) 
Normal weight, 2 metabolic abnormalities 1.57(1.50-1.64) 1.34(1.25-1.43) 1.34(1.25-1.43) 1.28(1.21-1.35) 1.31(1.22-1.40) 
Normal weight, 3 metabolic abnormalities 1.91(1.77-2.06) 1.74(1.52-1.98) 1.73(1.51-1.97) 1.56(1.41-1.74) 1.68(1.46-1.92) 
Overweight, 0 metabolic abnormalities 1.03(0.98-1.07) 1.03(0.99-1.07) 1.03(0.99-1.07) 1.00(0.97-1.03) 1.04(1.00-1.08) 
Overweight, 1 metabolic abnormality 1.37(1.32-1.43) 1.36(1.30-1.42) 1.36(1.30-1.42) 1.29(1.25-1.33) 1.37(1.31-1.42) 
Overweight, 2 metabolic abnormalities 1.51(1.45-1.57) 1.44(1.35-1.53) 1.43(1.35-1.52) 1.30(1.24-1.36) 1.40(1.32-1.49) 
Overweight, 3 metabolic abnormalities 1.87(1.76-1.99) 1.64(1.47-1.82) 1.63(1.46-1.81) 1.49(1.37-1.61) 1.65(1.48-1.83) 
Obese, 0 metabolic abnormalities 1.16(1.10-1.23) 1.11(1.07-1.16) 1.11(1.06-1.16) 1.07(1.04-1.11) 1.20(1.14-1.25) 
Obese, 1 metabolic abnormality 1.38(1.33-1.44) 1.39(1.33-1.46) 1.38(1.32-1.45) 1.30(1.26-1.35) 1.43(1.36-1.50) 
Obese, 2 metabolic abnormalities 1.55(1.49-1.62) 1.52(1.43-1.61) 1.51(1.42-1.60) 1.41(1.36-1.48) 1.59(1.49-1.69) 
Obese, 3 metabolic abnormalities 2.01(1.91-2.13) 1.76(1.62-1.90) 1.75(1.61-1.89) 1.50(1.41-1.61) 1.72(1.57-1.88) 
HR= Hazard Ratio; CI= Confidence interval; HRT= hormone replacement therapy 
*Model adjusted for age, sex, smoking status and social deprivation †Model adjusted for age, sex, smoking status, social deprivation and HRT 
‡Model adjusted for age, sex, smoking status, social deprivation and oral contraceptives 
§Women only 
||
 Model adjusted for age, sex, and social deprivation 
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Table S12 Sensitivity analysis results: Association between body size phenotype and metabolic status with heart failure by sex and age 
Body size phenotype and metabolic status Sex 
HR (95% CI)* 
Age (years) 
HR (95% CI)† 
 Male Female <65 ≥ 65 
Underweight, 0 metabolic abnormalities 1.08(0.87-1.34) 1.39(1.20-1.62) 1.41(1.13-1.75) 1.18(1.02-1.35) 
Underweight, 1 or more metabolic abnormalities 1.58(1.09-2.28) 1.54(1.26-1.87) 2.54(1.55-4.14) 1.33(1.11-1.60) 
Normal weight, 0 metabolic abnormalities 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Normal weight, 1 metabolic abnormality 1.34(1.24-1.45) 1.52(1.41-1.63) 1.72(1.52-1.95) 1.30(1.22-1.38) 
Normal weight, 2 metabolic abnormalities 1.26(1.11-1.43) 1.57(1.40-1.75) 2.21(1.84-2.65) 1.23(1.12-1.35) 
Normal weight, 3 metabolic abnormalities 1.55(1.21-1.98) 1.95(1.60-2.37) 3.38(2.34-4.88) 1.48(1.26-1.74) 
Overweight, 0 metabolic abnormalities 1.02(0.96-1.08) 1.19(1.11-1.28) 1.12(1.04-1.20) 1.12(1.05-1.19) 
Overweight, 1 metabolic abnormality 1.52(1.43-1.62) 1.70(1.58-1.83) 1.93(1.74-2.14) 1.47(1.39-1.55) 
Overweight, 2 metabolic abnormalities 1.62(1.50-1.76) 1.79(1.63-1.97) 2.39(2.11-2.70) 1.49(1.38-1.60) 
Overweight, 3 metabolic abnormalities 1.91(1.67-2.18) 2.21(1.91-2.56) 3.30(2.68-4.07) 1.74(1.56-1.95) 
Obese, 0 metabolic abnormalities 1.84(1.72-1.97) 2.05(1.91-2.21) 2.22(2.05-2.41) 1.84(1.72-1.97) 
Obese, 1 metabolic abnormality 2.56(2.39-2.75) 2.73(2.55-2.92) 3.51(3.21-3.84) 2.28(2.15-2.43) 
Obese, 2 metabolic abnormalities 2.76(2.54-3.00) 3.34(3.06-3.64) 4.33(3.90-4.80) 2.54(2.35-2.74) 
Obese, 3 metabolic abnormalities 3.48(3.11-3.90) 4.08(3.66-4.54) 5.99(5.28-6.80) 2.98(2.71-3.28) 
HR= Hazard Ratio; CI= Confidence interval 
*Model adjusted for age, smoking status and social deprivation †Model adjusted for sex, smoking status and social deprivation 
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Table S13 Sensitivity analysis results: Association between body size phenotype and metabolic status with heart failure using metabolic status derived from prescription 
records or measurement and exclusion of type 1 diabetes cases 
Body size phenotype and metabolic status Metabolic status 
derived from 
prescription records or 
measurement  
HR (95% CI)* 
Excluded  
Type 1 DM 
cases* 
Never smoked 
HR (95% CI) † 
 
Underweight, 0 metabolic abnormalities 1.16(0.95-1.41) 1.28(1.13-1.44) 1.33(1.10-1.60) 
Underweight, 1 or more metabolic abnormalities 1.75(1.54-1.98) 1.50(1.26-1.79) 1.73(1.37-2.19) 
Normal weight, 0 metabolic abnormalities 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Normal weight, 1 metabolic abnormality 1.43(1.34-1.53) 1.43(1.35-1.51) 1.54(1.43-1.66) 
Normal weight, 2 metabolic abnormalities 1.43(1.33-1.54) 1.39(1.28-1.51) 1.52(1.35-1.70) 
Normal weight, 3 metabolic abnormalities 2.09(1.86-2.34) 1.70(1.45-1.98) 1.84(1.48-2.28) 
Overweight, 0 metabolic abnormalities 1.12(1.03-1.21) 1.11(1.06-1.16) 1.17(1.09-1.25) 
Overweight, 1 metabolic abnormality 1.58(1.48-1.68) 1.61(1.53-1.70) 1.75(1.64-1.87) 
Overweight, 2 metabolic abnormalities 1.65(1.54-1.77) 1.69(1.59-1.81) 1.93(1.77-2.10) 
Overweight, 3 metabolic abnormalities 2.55(2.34-2.78) 2.00(1.81-2.22) 2.37(2.04-2.74) 
Obese, 0 metabolic abnormalities 1.99(1.82-2.18) 1.96(1.87-2.06) 2.11(1.96-2.29) 
Obese, 1 metabolic abnormality 2.68(2.51-2.87) 2.66(2.53-2.80) 2.96(2.77-3.16) 
Obese, 2 metabolic abnormalities 2.87(2.68-3.07) 3.03(2.84-3.23) 3.60(3.29-3.93) 
Obese, 3 metabolic abnormalities 4.46(4.12-4.83) 3.69(3.40-3.99) 4.23(3.79-4.72) 
HR= Hazard Ratio; CI= Confidence interval; HRT= hormone replacement therapy 
*Model adjusted for age, sex, smoking status and social deprivation †Model adjusted for age, sex, and social deprivation  
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Table S14 Sensitivity analysis results: Association between body size phenotype and metabolic status with peripheral vascular disease by sex and age 
Body size phenotype and metabolic status Sex 
HR (95% CI)* 
Age (years) 
HR (95% CI) † 
 Male Female <65 ≥ 65 
Underweight, 0 metabolic abnormalities 1.28(1.08-1.53) 1.42(1.23-1.64) 1.45(1.23-1.69) 1.22(1.06-1.41) 
Underweight, 1 or more metabolic abnormalities 1.60(1.19-2.15) 1.99(1.64-2.41) 2.31(1.71-3.11) 1.57(1.31-1.90) 
Normal weight, 0 metabolic abnormalities 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Normal weight, 1 metabolic abnormality 1.66(1.55-1.78) 1.82(1.68-1.98) 2.27(2.09-2.47) 1.37(1.29-1.47) 
Normal weight, 2 metabolic abnormalities 1.88(1.70-2.07) 2.44(2.19-2.72) 2.93(2.59-3.31) 1.66(1.52-1.82) 
Normal weight, 3 metabolic abnormalities 2.33(1.92-2.83) 2.75(2.21-3.42) 4.27(3.33-5.46) 1.85(1.56-2.19) 
Overweight, 0 metabolic abnormalities 0.89(0.85-0.95) 0.94(0.88-1.01) 0.94(0.89-1.00) 0.91(0.86-0.97) 
Overweight, 1 metabolic abnormality 1.42(1.34-1.51) 1.50(1.38-1.63) 1.70(1.58-1.83) 1.23(1.15-1.31) 
Overweight, 2 metabolic abnormalities 1.66(1.54-1.79) 1.81(1.63-2.01) 2.28(2.08-2.50) 1.34(1.23-1.46) 
Overweight, 3 metabolic abnormalities 2.30(2.05-2.57) 2.44(2.07-2.89) 3.46(2.98-4.03) 1.78(1.57-2.01) 
Obese, 0 metabolic abnormalities 0.93(0.86-1.00) 0.87(0.79-0.95) 1.02(0.95-1.10) 0.80(0.73-0.88) 
Obese, 1 metabolic abnormality 1.30(1.21-1.40) 1.39(1.27-1.52) 1.60(1.48-1.73) 1.10(1.01-1.19) 
Obese, 2 metabolic abnormalities 1.64(1.51-1.78) 2.00(1.80-2.23) 2.30(2.09-2.53) 1.35(1.24-1.48) 
Obese, 3 metabolic abnormalities 2.07(1.84-2.33) 2.22(1.92-2.58) 3.05(2.68-3.47) 1.49(1.31-1.69) 
HR= Hazard Ratio; CI= Confidence interval 
*Model adjusted for age, smoking status and social deprivation †Model adjusted for sex, smoking status and social deprivation 
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Table S15 Sensitivity analysis results: Association between body size phenotype and metabolic status with peripheral vascular disease using metabolic status derived from 
prescription records or measurement and different exclusions 
Body size phenotype and metabolic status Metabolic status 
derived from 
prescription 
records or 
measurement  
HR (95% CI)* 
Excluded  
Type 1 DM cases  
HR (95% CI)* 
Never smoked 
HR (95% CI) † 
 
Underweight, 0 metabolic abnormalities 1.46(1.24-1.72) 1.35(1.21-1.51) 1.36(1.04-1.77) 
Underweight, 1 or more metabolic abnormalities 2.12(1.89-2.38) 1.83(1.56-2.15) 1.55(1.07-2.25) 
Normal weight, 0 metabolic abnormalities 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Normal weight, 1 metabolic abnormality 1.62(1.52-1.72) 1.68(1.59-1.77) 1.81(1.63-2.01) 
Normal weight, 2 metabolic abnormalities 2.13(1.99-2.27) 2.00(1.86-2.15) 2.42(2.12-2.77) 
Normal weight, 3 metabolic abnormalities 3.35(3.00-3.73) 2.23(1.91-2.61) 2.58(1.98-3.35) 
Overweight, 0 metabolic abnormalities 0.96(0.90-1.03) 0.92(0.88-0.96) 0.97(0.89-1.06) 
Overweight, 1 metabolic abnormality 1.37(1.29-1.45) 1.42(1.35-1.49) 1.75(1.61-1.90) 
Overweight, 2 metabolic abnormalities 1.78(1.67-1.89) 1.66(1.55-1.77) 2.12(1.88-2.38) 
Overweight, 3 metabolic abnormalities 3.10(2.84-3.39) 2.25(2.03-2.49) 3.04(2.57-3.59) 
Obese, 0 metabolic abnormalities 0.93(0.84-1.03) 0.92(0.86-0.97) 1.11(1.00-1.24) 
Obese, 1 metabolic abnormality 1.38(1.29-1.48) 1.32(1.25-1.40) 1.66(1.49-1.85) 
Obese, 2 metabolic abnormalities 1.66(1.56-1.77) 1.73(1.62-1.85) 2.64(2.36-2.96) 
Obese, 3 metabolic abnormalities 2.82(2.58-3.09) 2.05(1.85-2.27) 3.05(2.56-3.64) 
HR= Hazard Ratio; CI= Confidence interval 
*Model adjusted for age, sex, smoking status and social deprivation †Model adjusted for age, sex, and social deprivation  
 
 
